

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
7 April 2005 (07.04.2005)

PCT

(10) International Publication Number
WO 2005/030758 A1

(51) International Patent Classification⁷: C07D 403/12,
401/12, 413/12, 417/12, 239/42, A61K 31/506, A61P 3/06

(21) International Application Number:
PCT/US2004/031212

(22) International Filing Date:
22 September 2004 (22.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/505,893 25 September 2003 (25.09.2003) US

(71) Applicant (for all designated States except US): **BRIS-
TOL-MYERS SQUIBB COMPANY** [US/US]; P.O. Box
4000, Route 206 and ProvinceLine Road, Princeton, NJ
08543-4000 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **AHMAD, Saleem**
[US/US]; 2094 Ohadi Drive, Wall, NJ 07719 (US). **ROBL,
Jeffrey, A.** [US/US]; 7 Tulip Drive, Newtown, PA 18940
(US). **NGU, Khehyong** [US/US]; 4 Kunkel Court, Pen-
nington, NJ 08534 (US).

(74) Agents: **RODNEY, Burton et al.**; Bristol-Myers Squibb
Company, P.O. Box 4000, Princeton, NJ 08543-4000 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.




(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,
EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,

[Continued on next page]

(54) Title: PYRIMIDINE AND PYRIDINE DERIVATIVES USEFUL AS HMG-COA REDUCTASE INHIBITORS AND METHOD OF PREPARATION THEREOF



(57) Abstract: Compounds are provided having the following structure which are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, dyslipidemia, hormone replacement therapy, hypercholesterolemia, hypertriglyceridemia and atherosclerosis as well as Alzheimer's disease and osteoporosis identified in Formula (I) wherein X is N or CR₅; and pharmaceutically acceptable salts thereof, Z is identified in Formula (II) or in Formula (III); wherein R₁ to R₇ are as defined herein. A method for treating the above diseases employing the above compounds is also provided.



TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.


PYRIMIDINE AND PYRIDINE DERIVATIVES USEFUL AS HMG-COA REDUCTASE INHIBITORS AND
METHOD OF PREPARATION THEREOF

FIELD OF THE INVENTION

The present invention relates to compounds and pharmaceutical compositions
5 useful as hypocholesterolemic and hypolipidemic agents. More particularly, this
invention concerns (1) certain inhibitors of the enzyme 3-hydroxy-3-methylglutaryl-
coenzyme A reductase (HMG-CoA reductase) that include a pyridine- or a
pyrimidine-containing nucleus attached by means of a linker to an HMG-binding
domain sidechain, (2) pharmaceutical compositions containing such compounds and
10 (3) a method of lowering blood serum cholesterol levels and modulating blood serum
lipid levels employing such pharmaceutical compositions.


BACKGROUND OF THE INVENTION

U.S. Patent No. 5,260,440 and Reissue 37314 disclose rosuvastatin which has
15 the structure




Rosuvastatin is also disclosed in Masamichi Watanabe et al. (Bioorganic &
20 Medicinal Chemistry (1997), 5(2), 437-444).

Japanese Patent Application 06256318-A (corresponding to Japanese Patent
3197971 granted August 1, 2001) discloses 5-carboalkoxy pyrimidine derivatives of
the structure



where R^1 , R^2 and R^3 can be independently H, alkyl, aryl or heteroaryl, and A can be NR^7R^8 where R^7 and R^8 can be independently H, alkyl, aryl and heteroaryl among
 5 others. It is disclosed that these compounds are intermediates for preparing HMG CoA reductase inhibitors.

Beck et al., Synthesis and Biological Activity of New HMG-CoA Reductase Inhibitors. 1. Lactones of Pyridine – and Pyrimidine-Substituted 3,5-Dihydroxy-6-heptenoic (-heptanoic) Acids, J. Med. Chem. 1990, 33, 52-60 (mentioned in Japanese
 10 Patent Application 06256318-A) discloses compounds of the structure




where Y can be CH or N;

- 15 A-B may be $-CH=CH-$;
 R^1 may be an alkyl including $i\text{-CH}_3\text{H}_7$;
 R^2 may be an aryl including $4\text{-FC}_6\text{H}_4$; and
 R^3 may be an alkyl or an aryl;


which compounds may be prepared from intermediates of the structure

20



EP367895 (mentioned in Japanese Patent Application 06256318-A) discloses pyrimidinyl-substituted hydroxyacids, lactones and esters which are inhibitors of cholesterol biosynthesis and have the structure

5



where R¹ can be alkyl;

Q can be aryl;

10


X can be -CH₂CH₂- or -CH=CH- ;

Y can be $\begin{array}{c} \text{R}^6 \\ | \\ \text{---CHCH}_2\text{CCH}_2\text{COOR}^7 \\ | \quad | \\ \text{OH} \quad \text{OH} \end{array}$ or a lactone thereof;

and R² can be -N(R⁸)₂ where each R⁸ is independently C₁-C₄ alkyl or both R⁸ together with the nitrogen atom form part of a 5-, 6- or 7-membered optionally substituted ring, which may contain a further oxygen heteroatom, preferably 4-morpholinyl. These

15

compounds may be prepared using intermediates of the structure




BRIEF DESCRIPTION OF THE INVENTION

20

In accordance with the present invention, there are provided certain pyridine- and pyrimidine-containing compounds that are potent inhibitors of cholesterol biosynthesis by virtue of their ability to inhibit the enzyme 3-methyl-glutaryl-coenzyme A reductase (HMG-CoA reductase).

25

In particular, in its broadest chemical compound aspect, the present invention provides compounds of the formula I




5 wherein X is N or CR₅;

R₁ and R₂ are the same or different and are independently selected from H, alkyl, alkoxyalkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl or cycloheteroalkyl;

R₃ is aryl, heteroaryl, cycloalkyl, or cycloheteroalkyl;

10 R₄ is H, alkyl, cycloalkyl, haloalkyl, alkoxyalkyl, alkylthioalkyl, alkylsulfonyl, arylsulfonyl, alkoxycarbonyl, aryloxy carbonyl, heteroaryloxy carbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkylthiocarbonyl, heteroarylaminocarbonyl, alkylaminosulfonyl, alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, or heteroarylsulfonyl;

15 R₅ is H or lower alkyl;



20 R₆ is H, or lower alkyl or a metal ion (such as an alkali metal or an alkaline earth metal);

R₇ is H or lower alkyl;

and represents a single bond or a double bond (which may be cis or trans);

and including pharmaceutically acceptable salts thereof where R_6 is H, esters thereof, prodrug esters thereof, and all stereoisomers thereof.

Preferably, the Z group will be in form of a free acid, a physiologically acceptable and hydrolyzable ester or δ lactone thereof, or an alkali metal salt, alkaline earth metal salt, an amine salt or an amino acid salt.

Preferred are compounds of formula I of the invention wherein

R_1 and R_2 are independently selected from alkyl, cycloalkyl and aryl;

R_3 is aryl, heteroaryl or cycloheteroalkyl;

R_4 is H, alkyl, lower alkylcarbonyl, lower alkylsulfonyl or lower alkoxycarbonyl.


More preferred are compounds of formula I of the invention wherein R_1 is aryl (especially substituted aryl as defined hereinafter);

R_2 is alkyl or cycloalkyl;

R_3 is aryl, heteroaryl or cycloheteroalkyl;

R_4 is H, alkyl, lower alkylcarbonyl, lower alkylsulfonyl, lower alkoxycarbonyl;

and  is a double bond, preferably "trans" and



or an alkali or alkaline earth metal salt thereof, or an amino acid salt thereof, or an amine salt thereof.

Still more preferred are compounds of formula I of the invention wherein


R_1 is substituted aryl, preferably 4-fluorophenyl, 4-fluoro-3-methylphenyl or 3,5-dimethylphenyl;

R_2 is alkyl or cycloalkyl, preferably isopropyl, t-butyl or cyclopropyl;

R₃ is aryl (preferably phenyl), cycloheteroalkyl (preferably tetrahydrothiophene dioxide), or heteroaryl (preferably a pyrazole, thiadiazole, pyrimidine, pyrazine, benzimidazole, triazole, tetrazole, pyridyl, thiazole, oxazole or isoxazole) wherein the above groups may be optionally substituted with 1, 2 or 3 substituents which may be alkylaminocarbonyl, cycloheteroalkyl, heteroaryl, alkyl, halogen, carboxyl, alkoxy carbonyl or alkoxy;


R₄ is H, C₁-C₄ alkyl, preferably methyl, C₁-C₄ alkylcarbonyl, preferably methylcarbonyl or C₁-C₄ alkylsulfonyl, preferably methanesulfonyl;

== is a double bond, preferably "trans" and



or an alkali or alkaline earth metal salt thereof or an amino acid salt thereof or an amine salt thereof.


15 Most preferred compounds of formula I of the invention will have the structure



or an alkali or alkaline earth metal (such as Na, K or Ca) salt thereof, or an amino acid
20 salt (such as arginine), or an amine salt thereof, wherein R₈ and R₉ are the same or
different and independently selected from H, halogen and/or alkyl (preferably 4-
fluoro, 4-fluoro-3-methyl or 3,5-dimethyl); and

R₂ is alkyl or cycloalkyl, preferably isopropyl, t-butyl or cyclopropyl;

R_3 is one of the following groups:



10 R₄ is H, alkyl, preferably methyl, or 4-methoxybenzyl, C₁-C₄ alkylcarbonyl, preferably methylcarbonyl, C₁-C₄ alkoxy carbonyl, preferably methoxycarbonyl or C₁-C₄ alkylsulfonyl, preferably methanesulfonyl;

R₅ is methyl.

In another aspect, the present invention provides pharmaceutical compositions, useful as hypolipidemic or hypocholesterolemic agents, or hypotriglyceridemic agents, or anti-Alzheimer's agents, or anti-osteoporosis agents as well as other uses as described herein, which contain a hypolipidemic or hypocholesterolemic or
5 hypotriglyceridemic or anti-Alzheimer's disease or anti-osteoporosis amount, or other therapeutically effective amount (depending upon use) of a compound of formula I in accordance with this invention, in combination with a pharmaceutically acceptable carrier.

In another aspect, the present invention provides a method of inhibiting
10 cholesterol biosynthesis or lowering blood serum cholesterol levels and/or modulating blood serum cholesterol levels such as lowering LDL cholesterol and/or increasing HDL cholesterol, and/or lowering triglycerides, or treating dyslipidemia, mixed
dyslipidemia, hyperlipidemia, hypercholesterolemia, hypo α -lipoproteinemia, LDL Pattern B, LDL Pattern A, hyperlipoproteinemia or hypertriglyceridemia, and other
15 aberrations of apolipoprotein B metabolism, or reducing levels of Lp(a), or treating or preventing other cholesterol-related diseases, or treating or preventing or reversing progression of atherosclerosis, or preventing or treating Alzheimer's disease, or preventing or treating osteoporosis and/or osteopenia, or reducing inflammatory markers such as C-reactive protein, or preventing or treating low grade vascular
20 inflammation, or preventing or treating stroke, or preventing or treating dementia, or preventing and treating coronary heart disease (including primary and secondary prevention of myocardial infarction), or preventing or treating stable and unstable angina, or primary prevention of coronary events, or secondary prevention of cardiovascular events, or preventing or treating peripheral vascular disease, preventing
25 or treating peripheral arterial disease, or preventing or treating acute vascular syndromes, or preventing or reducing the risk of undergoing myocardial revascularization procedures, or preventing or treating microvascular diseases such as nephropathy, neuropathy, retinopathy and nephrotic syndrome or preventing or treating hypertension in a patient in need of such treatment by administering a
30 therapeutically effective amount of a compound of structure I or pharmaceutical composition containing same in accordance with the present invention as defined above.

In addition, in accordance with the present invention, a method is provided for preventing or treating diabetes, especially Type 2 diabetes, and related diseases such as insulin resistance, hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids or glycerol, obesity, Syndrome X, diabetic complications, dysmetabolic syndrome, and related diseases, and sexual dysfunction, wherein a therapeutically effective amount of a compound of structure I or composition containing same is administered to a patient in need of treatment.

In addition, in accordance with the present invention, a method is provided for preventing and treating malignant lesions (such as ductal carcinoma in situ of the breast and lobular carcinoma in situ of the breast), premalignant lesions (such as fibroadenoma of the breast and prostatic intraepithelial neoplasia (PIN), gastrointestinal malignancies, liposarcomas and various other epithelial tumors (including breast, prostate, colon, ovarian, gastric and lung), cancer-induced asthenia (fatigue), irritable bowel syndrome, Crohn's disease, gastric ulceritis, and gallstones, and HIV infection, other infectious diseases, drug-induced lipodystrophy, and proliferative diseases such as psoriasis, wherein a therapeutically effective amount of a compound of structure I or a composition containing same is administered to a human patient in need of treatment.

In addition, in accordance with the present invention, a method is provided for improving coagulation homeostasis including reducing plasminogen activating inhibitor (PAI)-1 activity, reducing fibrinogen, and/or reducing platelet aggregation, and/or improving endothelial function, wherein a therapeutically effective amount of a compound of structure I or a composition containing same is administered to a patient in need of treatment.

In addition, in accordance with the present invention, a method is provided for treating cholesterol related diseases, diabetes and related diseases, cardiovascular diseases, cerebrovascular diseases as defined above and hereinafter and other diseases as set out above, wherein a therapeutically effective amount of a combination of a compound of structure I and a hypolipidemic agent, and/or lipid modulating agent and/or antidiabetic agent and/or cardiovascular agent, cerebrovascular agent, and/or other type of therapeutic agent, is administered to a patient in need of treatment.

In the above methods of the invention wherein a combination is administered, the compound of structure I will be employed in a weight ratio to the other therapeutic agent (depending upon its mode of operation) within the range from about 0.01:1 to about 500:1, preferably from about 0.5:1 to about 100:1.

5

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention, there is provided compounds useful in inhibiting the enzyme HMG-CoA reductase, which inhibitors are useful as hypocholesterolemic agents, dyslipidemic agents, hypolipidemic agents, hypotriglyceridemic agents, anti-Alzheimer's disease agents, and antiosteoporosis agents as well as other uses as described herein.

The term "coronary events" as employed herein refers to myocardial infarction, myocardial revascularization procedures, angina, cardiovascular death and acute coronary syndrome.

15 The term "cardiovascular diseases or events" as employed herein refers to atherosclerosis of the coronary arteries, myocardial infarction, including primary MI and secondary MI, recurrent myocardial infarction, angina pectoris (including stable and unstable angina), congestive heart failure, and sudden cardiac death.

20 The term "cerebrovascular diseases or events" as employed herein refers to cerebral infarction or stroke (caused by vessel blockage or hemorrhage), or transient ischemia attack (TIA), syncope, atherosclerosis of the intracranial and/or extracranial arteries, and the like.

The term "cholesterol-related diseases" as employed herein refers to diseases involving elevated levels of LDL cholesterol, diseases involving regulation of LDL receptors, diseases involving reduced levels of HDL cholesterol, dyslipidemia, hyperlipidemia, elevated LDL Pattern B, elevated LDL Pattern A, hypercholesterolemia, hypo α -lipoproteinemia (low HDL cholesterol syndrome), hyperlipoproteinemia, elevated Lp(a) levels, hypertriglyceridemia, other aberrations of apolipoprotein B metabolism, heterozygous familial, presumed familial combined and non-familial (non-FH) forms of primary hypercholesterolemia (including Frederickson Types IIa and IIb), cholesterol ester storage disease, and cholesterol ester transfer protein disease, and related diseases.

30

The conditions, diseases, and maladies collectively referenced to as "Syndrome X" or Dysmetabolic Syndrome (as detailed in Johanson, *J. Clin. Endocrinol. Metab.*, **1997**, 82, 727-734, and other publications) include hyperglycemia and/or prediabetic insulin resistance syndrome, and is characterized by an initial insulin resistant state generating hyperinsulinemia, dyslipidemia, and impaired glucose tolerance, which can progress to Type II diabetes, characterized by hyperglycemia, which can progress to diabetic complications.

The term "diabetes and related diseases" refers to Type II diabetes, Type I diabetes, impaired glucose tolerance, obesity, hyperglycemia, Syndrome X, dysmetabolic syndrome, diabetic complications and hyperinsulinemia.

The conditions, diseases and maladies collectively referred to as "diabetic complications" include retinopathy, neuropathy and nephropathy, and other known complications of diabetes.

The term "other type(s) of therapeutic agents" as employed herein refers to one or more antidiabetic agents (other than compounds of formula I), one or more anti-obesity agents, and/or one or more lipid-lowering agents, one or more lipid modulating agents (including anti-atherosclerosis agents), other types of anti-atherosclerosis agents, and/or one or more antiplatelet agents, one or more agents for treating hypertension, one or more anti-cancer drugs, one or more agents for treating arthritis, one or more anti-osteoporosis agents, one or more agents for treating immunomodulatory diseases, and/or one or more agents for treating anorexia nervosa.

The term "lipid-modulating" agent as employed herein refers to agents which lower LDL and/or raise HDL and/or lower triglycerides and/or lower total cholesterol and/or other known mechanisms for therapeutically treating lipid disorders.

The term "other types of anti-atherosclerosis agents" as employed herein refers to conventional anti-atherosclerosis agents including lipoxxygenase inhibitors, ACAT inhibitors, PPAR α agonists, dual PPAR α / γ agonists, CETP inhibitors, antioxidants, PPAR δ agonists, phospholipase inhibitors including PLA-2 inhibitors and/or other known anti-atherosclerotic agents.

The terms pharmaceutically acceptable "salt" and "salts" refer to basic salts formed with inorganic and organic bases. Such salts include ammonium salts; alkali metal salts, such as lithium, sodium and potassium salts; alkaline earth metal salts,

such as calcium and magnesium salts; salts with organic bases, such as amine like salts (e.g., dicyclohexylamine salt, benzathine, N-methyl-D-glucamine, and hydrabamine salts); and salts with amino acids like arginine, lysine and the like; and zwitterions, the so-called "inner salts". Nontoxic, pharmaceutically acceptable salts
5 are preferred, although other salts are also useful, e.g., in isolating or purifying the product. Preferred are sodium and calcium salts.

The term pharmaceutically acceptable "salt" and "salts" also includes acid addition salts. These are formed, for example, with strong inorganic acids, such as mineral acids, for example sulfuric acid, phosphoric acid or a hydrohalic acid such as
10 HCl or HBr, with strong organic carboxylic acids, such as alkanecarboxylic acids of 1 to 4 carbon atoms which are unsubstituted or substituted, for example, by halogen, for example acetic acid, such as saturated or unsaturated dicarboxylic acids, for example oxalic, malonic, succinic, maleic, fumaric, phthalic or terephthalic acid, such as hydroxycarboxylic acids, for example ascorbic, glycolic, lactic, malic, tartaric or citric
15 acid, such as amino acids, (for example aspartic or glutamic acid or lysine or arginine), or benzoic acid, or with organic sulfonic acids, such as (C₁-C₄) alkyl or arylsulfonic acids which are unsubstituted or substituted, for example by halogen, for example methanesulfonic acid or p-toluenesulfonic acid.

Where the compounds of structure I are in acid form they may form a
20 pharmaceutically acceptable salt such as alkali metal salts such as lithium, sodium or potassium, alkaline earth metal salts such as calcium or magnesium as well as zinc or aluminum and other cations such as ammonium or choline, amino acid salts such as lysine (D or L), amine salts such as diethanolamine, ethylenediamine, t-butylamine, t-octylamine, tris- (hydroxymethyl)aminomethane (TRIS), N-methyl glucosamine
25 (NMG), triethanolamine, dicyclohexylamine, methylamine and dehydroabietylamine.

Following are definitions of various groups which may be substituted with 1 to 4 or more substituents. It will be understood that the various substituents may be the same or different at each occurrence. These substituents may occur at any place and in any combination that provides a stable compound.

30 Unless otherwise indicated, the term "alkyl" or "alk" as employed herein alone or as part of another group includes both straight and branched chain hydrocarbons, containing 1 to 20 carbons, preferably 1 to 10 carbons, more preferably 1 to 8 carbons,

in the normal chain, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethyl-pentyl, nonyl, decyl, undecyl, dodecyl, the various branched chain isomers thereof, and the like. Lower alkyl refers to such groups containing 1-6 carbon atoms. Unless specified

5 otherwise, alkyl groups may be optionally substituted with 1 to 4 substituents. The substituents include halo, for example F, Br, Cl or I or CF₃, alkyl, alkoxy, aryl, aryloxy, aryl(aryl) or diaryl, arylalkyl, arylalkyloxy, alkenyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkyloxy, amino, hydroxy, hydroxyalkyl, acyl, cycloheteroalkyl, heteroaryl, heteroaryloxy, heteroarylalkyl, heteroarylalkoxy,

10 aryloxyalkyl, alkylthio, arylalkylthio, aryloxyaryl, alkylamido, alkanoylamino, arylcarbonylamino, nitro, cyano, thiol, haloalkyl, trihaloalkyl and/or alkylthio,

OR₁₄,

alkyl which may be substituted with one or more occurrences of R₁₅,

alkenyl which may be substituted with one or more occurrences of R₁₅,

15 alkynyl which may be substituted with one or more occurrences of R₁₅,

cycloalkyl which may be substituted with one or more occurrences of R₁₅,

aryl which may be substituted with one or more occurrences of R₁₅,

heterocyclo which may be substituted with one or more occurrences of R₁₅,

SR₁₄,

20 SO₂R₁₄,

COOR₁₄,

C(O)R₁₄,

CONR₁₆R₁₇,

SO₂NR₁₆R₁₇,

25 SO₂N(H)C(O)R₁₄,

SO₂N(H)CO₂R₁₄, wherein R₁₄ is not H,

NR₁₆R₁₇,

N(R₁₆)SO₂R₁₇,

N(R₁₆)C(O)_mR₁₇ (m = 1,2),


30 N(R₁₆)C(O)NR₁₇R₁₈,

N(R₁₆)SO₂NR₁₇R₁₈,

OC(O)R₁₄,

- OC(O)OR_{14} ,
 $\text{OC(O)NR}_{17}\text{R}_{18}$,
 $\text{C(O)N(H)SO}_2\text{NR}_{17}\text{R}_{18}$,
 $\text{C(O)N(H)SO}_2\text{R}_{17}$,
5 oxo (or keto, i.e. =O),
thioxo (i.e., =S),
imino (i.e., =NR₁₉),
 $\text{NR}_{19}\text{-C(=NR}_{20})\text{R}_{21}$,
 $\text{NR}_{19}\text{-C(=NR}_{20})\text{NR}_{21}\text{R}_{22}$,
10 $\text{C(=NR}_{19})\text{NR}_{20}\text{R}_{21}$,
 $\text{OC(=NR}_{19})\text{NR}_{20}\text{R}_{21}$,
 $\text{OC(=NR}_{19})\text{R}_{20}$,
 $\text{C(=NR}_{19})\text{R}_{20}$,
 $\text{C(=NR}_{19})\text{OR}_{14}$,
15 R₁₄ is selected from H, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, C₃-C₈ cycloalkyl, C₆-C₁₀ aryl, or C₁-C₉ heterocyclo each of which may be substituted with 1 to 3 independent occurrences of R₁₅,
R₁₆, R₁₇, and R₁₈ are independently selected from C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, C₃-C₈ cycloalkyl, C₆-C₁₀ aryl, or C₁-C₉ heterocyclo each of which may
20 be substituted with 1 to 3 independent occurrences of R₁₅, or R₁₆ and R₁₇, or R₁₆ and R₁₈ or R₁₇ and R₁₈ may be joined by an alkylene or an alkenylene chain to form a 5- to 8-membered heterocyclo ring which is defined as for heterocyclo wherein the substituents may be one or more occurrences of R₁₅,
R₁₉, R₂₀, R₂₁, or R₂₂ are independently selected from H, nitro, cyano, OH, O(C₁-
25 C₆ alkyl), C(O)R₁₄, C(O)NR₁₆R₁₇, CO₂R₁₄ (with the proviso that R₁₄ is not H), SO₂R₁₄, SO₂NR₁₆R₁₇, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, C₃-C₈ cycloalkyl, C₆-C₁₀ aryl, or C₁-C₉ heterocyclo or R₁₉ and R₂₀ or R₁₉ and R₂₁ or R₁₉ and R₂₂ or R₂₀ and R₂₁ or R₂₀ and R₂₂ or R₂₁ and R₂₂ may be joined by an alkylene or alkenylene chain to form a 5-8 membered ring that may be optionally substituted with one or
30 more occurrences of R₁₅.
R₁₅ is selected from
halogen,

- nitro,
 cyano,
 OR₂₄,
 alkyl optionally substituted with halogen,
 5 cycloalkyl optionally substituted with halogen,
 aryl optionally substituted with halogen, hydroxy, nitro, methoxy,
 trifluoromethyl, cyano, carbomethoxy, CONH₂, or CHO,
 heterocyclo optionally substituted with halogen, hydroxy, nitro, methoxy,
 trifluoromethyl, cyano, carbomethoxy, CONH₂, or CHO,
 10 SR₂₄,
 CO₂R₂₄,
 C(O)R₂₄,
 CONR₂₅R₂₆,
 SO₂NR₂₅R₂₆,
 15 NR₂₅R₂₆,
 N(R₂₅)SO₂R₂₆,
 N(R₂₅)C(O)_mR₂₆ (m = 1,2),
 N(R₂₅)C(O)NR₂₆R₂₇,
 N(R₂₅)SO₂NR₂₆R₂₇,
 20 OC(O)R₂₄,
 OC(O)OR₂₄,
 SO₂R₂₄,
 SO₂N(H)C(O)R₂₄,
 SO₂N(H)CO₂R₂₄ wherein R₂₄ is not H,
 25 C(O)N(H)SO₂NR₂₅SR₂₆,
 C(O)N(H)SO₂R₂₄,
 OC(O)NR₂₅R₂₆,
 NR₂₈-C(=NR₂₉)R₃₀,
 NR₂₈-C(=NR₂₉)OR₂₄,
 30 NR₂₈-C(=NR₂₉)NR₃₀R₃₁,
 C(=NR₂₈)NR₂₉R₃₀,
 OC(=NR₂₈)R₂₉,




R_{24} is selected from unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted unsubstituted cycloalkyl, unsubstituted aryl, unsubstituted heterocyclo,

- 5 R_{25} , R_{26} and R_{27} are selected from unsubstituted alkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted cycloalkyl, unsubstituted aryl, unsubstituted heterocyclo, or R_{25} and R_{26} or R_{25} and R_{27} or R_{26} and R_{27} may be joined by an alkylene or alkenylene chain to form a 5-8 membered unsubstituted heterocyclo ring, and

- 10 R_{28} , R_{29} , R_{30} , R_{31} are selected from nitro, cyano, unsubstituted alkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted cycloalkyl, unsubstituted aryl, unsubstituted heterocyclo, or R_{28} and R_{29} , or R_{28} and R_{30} or R_{28} and R_{31} or R_{29} and R_{30} or R_{29} and R_{31} or R_{30} and R_{31} may be joined by an alkylene chain to form a 5- to 8-membered unsubstituted heterocyclo ring.

- 15 Unless otherwise indicated, the term "cycloalkyl" as employed herein alone or as part of another group includes saturated or partially unsaturated (containing 1 or 2 double bonds) cyclic hydrocarbon groups containing 1 to 3 rings, including monocyclic alkyl, bicyclic alkyl (or bicycloalkyl) and tricyclic alkyl, containing a total of 3 to 20 carbons forming the ring, preferably 3 to 10 carbons, forming the ring and
20 which may be fused to 1 or 2 aromatic rings as described for aryl, which includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl and cyclododecyl, cyclohexenyl,



25



any of which groups may be optionally substituted with 1 to 4 substituents, which may be the same or different at each occurrence, such as halogen, alkyl, alkoxy, hydroxy, aryl, aryloxy, arylalkyl, cycloalkyl, alkylamido, alkanoylamino, oxo, acyl, arylcarbonylamino, heteroaryl, cycloheteroalkyl, amino, alkylamino, nitro, cyano, thiol and/or alkylthio and/or any of the substituents for alkyl.

The term "cycloalkenyl" as employed herein alone or as part of another group refers to cyclic hydrocarbons containing 3 to 12 carbons, preferably 5 to 10 carbons and 1 or 2 double bonds. Exemplary cycloalkenyl groups include cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclohexadienyl, and cycloheptadienyl, which may be optionally substituted as defined for cycloalkyl.

The term "alkanoyl" or "alkylcarbonyl" as used herein alone or as part of another group refers to alkyl linked to a carbonyl group.

Unless otherwise indicated, the term "lower alkenyl" or "alkenyl" as used herein by itself or as part of another group refers to straight or branched chain radicals of 2 to 20 carbons, preferably 2 to 12 carbons, and more preferably 1 to 8 carbons in the normal chain, which include one to six double bonds in the normal chain, such as vinyl, 2-propenyl, 3-butenyl, 2-butenyl, 4-pentenyl, 3-pentenyl, 2-hexenyl, 3-hexenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 3-octenyl, 3-nonenyl, 4-decenyl, 3-undecenyl, 4-dodecenyl, 4,8,12-tetradecatrienyl, and the like, and which may be optionally substituted with 1 to 4 substituents, namely, halogen, haloalkyl, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, amino, hydroxy, heteroaryl, cycloheteroalkyl, alkanoylamino, alkylamido, arylcarbonyl-amino, nitro, cyano, thiol, alkylthio and/or any of the alkyl substituents set out herein.

Unless otherwise indicated, the term "lower alkynyl" or "alkynyl" as used herein by itself or as part of another group refers to straight or branched chain radicals of 2 to 20 carbons, preferably 2 to 12 carbons and more preferably 2 to 8 carbons in the normal chain, which include one triple bond in the normal chain, such as 2-propynyl, 3-butynyl, 2-butynyl, 4-pentynyl, 3-pentynyl, 2-hexynyl, 3-hexynyl, 2-heptynyl, 3-heptynyl, 4-heptynyl, 3-octynyl, 3-nonyl, 4-decynyl, 3-undecynyl, 4-dodecynyl and the like, and which may be optionally substituted with 1 to 4 substituents, namely, halogen, haloalkyl, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, amino, heteroaryl, cycloheteroalkyl, hydroxy, alkanoylamino,

alkylamido, arylcarbonylamino, nitro, cyano, thiol, and/or alkylthio, and/or any of the alkyl substituents set out herein.

The terms "arylalkenyl" and "arylalkynyl" as used alone or as part of another group refer to alkenyl and alkynyl groups as described above having an aryl
5 substituent.


Where alkyl groups as defined above have single bonds for attachment to other groups at two different carbon atoms, they are termed "alkylene" groups and may optionally be substituted with 1 or 2 substituents as defined above for "alkyl", such as, for example, alkyl, halo, hydroxy, alkoxy and/or cycloalkyl.

10 Where alkenyl groups as defined above and alkynyl groups as defined above, respectively, have single bonds for attachment at two different carbon atoms, they are termed "alkenylene groups" and "alkynylene groups", respectively, and may optionally be substituted with 1 or 2 substituents as defined above for "alkenyl" and "alkynyl".

The term "halogen" or "halo" as used herein alone or as part of another group
15 refers to chlorine, bromine, fluorine, and iodine as well as CF₃, with chlorine or fluorine being preferred.

The term "metal ion" refers to alkali metal ions such as sodium, potassium or lithium and alkaline earth metal ions such as magnesium and calcium, as well as zinc and aluminum.

20 Unless otherwise indicated, the term "aryl" as employed herein alone or as part of another group refers to monocyclic and bicyclic aromatic groups containing 6 to 10 carbons in the ring portion (such as phenyl or naphthyl including 1-naphthyl and 2-naphthyl) and may optionally include one to three additional rings fused to a carbocyclic ring or a heterocyclic ring (such as aryl, cycloalkyl, heteroaryl or
25 cycloheteroalkyl rings for example



and may be optionally substituted through available carbon atoms with 1, 2, or 3 groups selected from hydrogen, halo, haloalkyl, alkyl, haloalkyl, alkoxy, halophenyl, benzoyloxy, haloalkoxy, alkenyl, trifluoromethyl, trifluoromethoxy, alkynyl, cycloalkyl-alkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, arylalkoxy, arylalkoxyalkyl, arylalkoxy, arylthio, arylazo, heteroarylalkyl, heteroarylalkenyl, heteroarylheteroaryl, heteroaryloxy, hydroxy, nitro, cyano, amino, substituted amino wherein the amino includes 1 or 2 substituents (which are alkyl, alkanoyl, aryl or any of the other aryl compounds mentioned in the definitions), thiol, alkylthio, arylthio, heteroarylthio, arylthioalkyl, alkoxyarylthio, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkylcarbonylamino, arylcarbonylamino, arylsulfinyl, arylsulfinylalkyl, arylsulfonylamino or arylsulfonaminocarbonyl and/or any of the alkyl substituents set out herein.

Unless otherwise indicated, the term "lower alkoxy", "alkoxy", "aryloxy" or "aralkoxy" as employed herein alone or as part of another group includes any of the above alkyl, aralkyl or aryl groups linked to an oxygen atom.

Unless otherwise indicated, the term "substituted amino" as employed herein alone or as part of another group refers to amino substituted with one or two substituents, which may be the same or different, such as alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl or thioalkyl. These substituents may be further substituted with a carboxylic acid and/or any of the substituents for alkyl as set out above. In addition, the amino substituents may be taken together with


the nitrogen atom to which they are attached to form 1-pyrrolidinyl, 1-piperidinyl, 1-azepinyl, 4-morpholinyl, 4-thiamorpholinyl, 1-piperazinyl, 4-alkyl-1-piperazinyl, 4-arylalkyl-1-piperazinyl, 4-diarylalkyl-1-piperazinyl, 1-pyrrolidinyl, 1-piperidinyl, or 1-azepinyl, optionally substituted with alkyl, alkoxy, alkylthio, halo, trifluoromethyl or hydroxy.

Unless otherwise indicated, the term "lower alkylthio", "alkylthio", "arylthio" or "aralkylthio" as employed herein alone or as part of another group includes any of the above alkyl, aralkyl or aryl groups linked to a sulfur atom.


Unless otherwise indicated, the term "lower alkylamino", "alkylamino", "arylamino", or "arylalkylamino" as employed herein alone or as part of another group includes any of the above alkyl, aryl or arylalkyl groups linked to a nitrogen atom.

Unless otherwise indicated, the term "acyl" as employed herein by itself or part of another group, as defined herein, refers to an organic radical linked to a carbonyl ($\text{C}(=\text{O})$) group; examples of acyl groups include any of the R_1 or R_4 groups attached to a carbonyl, such as alkanoyl, alkenoyl, aroyl, aralkanoyl, heteroaroyl, cycloalkanoyl, cycloheteroalkanoyl and the like.

Unless otherwise indicated, the term "cycloheteroalkyl" as used herein alone or as part of another group refers to a 5-, 6- or 7-membered saturated or partially unsaturated ring which includes 1 to 2 hetero atoms such as nitrogen, oxygen and/or sulfur, linked through a carbon atom or a heteroatom, where possible, optionally via the linker $(\text{CH}_2)_r$ (where r is 1, 2 or 3), such as





25



5 and the like. The above groups may include 1 to 4 substituents such as alkyl, halo, oxo and/or any of of the alkyl substituents set out herein. In addition, any of the cycloheteroalkyl rings can be fused to a cycloalkyl, aryl, heteroaryl or cycloheteroalkyl ring.

Unless otherwise indicated, the term "heteroaryl" as used herein alone or as part of another group refers to a 5- or 6- membered aromatic ring which includes 1, 2, 3 or 4 hetero atoms such as nitrogen, oxygen or sulfur, and such rings fused to an aryl, cycloalkyl, heteroaryl or cycloheteroalkyl ring (e.g. benzothiophenyl, indolyl), and includes possible N-oxides. The heteroaryl group may optionally include 1 to 4 substituents such as any of the substituents set out above for alkyl. Examples of heteroaryl groups include the following:





10 and the like.

The term "cycloheteroalkylalkyl" as used herein alone or as part of another group refers to cycloheteroalkyl groups as defined above linked through a C atom or heteroatom to a $(CH_2)_r$ chain.



15 The term "heteroarylalkyl" or "heteroarylalkenyl" as used herein alone or as part of another group refers to a heteroaryl group as defined above linked through a C atom or heteroatom to a $-(CH_2)_r$ chain, alkylene or alkenylene as defined above.

The term "polyhaloalkyl" as used herein refers to an "alkyl" group as defined above which includes from 2 to 9, preferably from 2 to 5, halo substituents, such as F or Cl, preferably F, such as CF_3CH_2 , CF_3 or $\text{CF}_3\text{CF}_2\text{CH}_2$.

The term "heterocyclo" or "heterocyclyl" as used herein refers to heteroaryl
5 and cycloheteroalkyl.

The term "polyhaloalkoxy" as used herein refers to an "alkoxy" or "alkyloxy" group as defined above which includes from 2 to 9, preferably from 2 to 5, halo substituents, such as F or Cl, preferably F, such as $\text{CF}_3\text{CH}_2\text{O}$, CF_3O or $\text{CF}_3\text{CF}_2\text{CH}_2\text{O}$.

10 As defined above, alkyl, alkenyl, alkynyl, cycloalkyl, and heterocyclo groups may be attached through one or more single bonds to one or more attachment atoms. In addition, these groups may be attached by double bonds to attachment atoms, and these groups may be referred to as 'alkylidene', 'alkenylidene', 'alkynylidene', 'cycloalkylidene' or 'heterocyclidene' groups. Examples include methyldiene ($=\text{CH}_2$),

15 ethylidene ($=\text{CHCH}_3$), ethenylidene ($=\text{C}=\text{CH}_2$), cyclohexylidene () and 2-pyranylidene () . These groups may be substituted as described above for alkyl, alkenyl, alkynyl, cycloalkyl, and heterocyclo.


All stereoisomers of the compounds of the instant invention are contemplated, either in admixture or in pure or substantially pure form. The compounds of the
20 present invention can have asymmetric centers at any of the carbon atoms including any one or the R substituents. Consequently, compounds of formula I can exist in enantiomeric or diastereomeric forms or in mixtures thereof. The processes for preparation can utilize racemates, enantiomers or diastereomers as starting materials. When diastereomeric or enantiomeric products are prepared, they can be separated by
25 conventional methods for example, chromatographic or fractional crystallization.

The compounds of the present invention can have asymmetric centers at certain of the nitrogen atoms. Consequently, these isomers or mixtures thereof are part of the present invention.


The compounds of the present invention may also display other instances of chirality, such as atropoisomerism. Thus, these isomers or mixtures thereof are part of the invention.

The term "prodrug esters" as employed herein includes esters and carbonates formed by reacting one or more hydroxyls of compounds of formula I with alkyl, alkoxy, or aryl substituted acylating agents employing procedures known to those skilled in the art to generate acetates, pivalates, methylcarbonates, benzoates and the like. In addition, prodrug esters which are known in the art for carboxylic and phosphorus acid esters such as methyl, ethyl, benzyl and the like are included herein.

Examples of such prodrug esters include




Other examples of suitable prodrug esters include



wherein R^a can be H, alkyl (such as methyl or t-butyl), arylalkyl (such as benzyl) or aryl (such as phenyl); R^d is H, alkyl, halogen or alkoxy, R^e is alkyl, aryl, arylalkyl or alkoxy, and n_1 is 0, 1 or 2.

Compounds of the invention may be prepared by the following methods (Schemes 1-4).

SCHEME 1



Scheme 1 outlines synthesis of the compounds of formula I where X = N. The previously known ester 1 (Masamichi Watanabe et al. Bioorganic & Medicinal Chemistry (1997), 5(2), 437-444; Eur. Pat. App. 1993, 18 pp. EP 521471) can be reduced by using DIBAL in toluene or methylene chloride to afford the alcohol 2. Compound 2 can be oxidized by using Dess-Martin's periodinane in methylene chloride or by using buffered bleach (NaOCl) in the presence of catalytic amounts of TEMPO free radical and potassium bromide in methylene chloride or ethyl acetate to afford aldehyde 3. Compound 3 can be converted to the key intermediate olefin 4 by reaction with the previously known sulfone 5 (Brodfehrer, Paul R. et al. PCT Int. Appl. (2002), WO 0298854) and an organic base such as lithium, sodium or potassium bistrimethylsilyl amide. Treatment of compound 4 with an aryl amine, a cycloheteroalkylamine or a heteroarylamine 5a in the presence of a base such as lithium, sodium or potassium bistrimethylsilyl amide in THF or DMF affords 6. Compounds of formula 6 can be converted to certain compounds of the formula I ($R_4 = H$, compound 1b) by treatment with an aqueous protic acid such as hydrochloric acid, sulfuric acid or p-toluenesulfonic acid to give 1a followed by saponification with an aqueous base such as sodium hydroxide to give 1b.


Alternatively, 6 can be converted to compounds of the formula I (R_4 is other than H, such as alkyl, alkylsulfonyl, alkanoyl, alkoxy carbonyl etc., compound 1c) by an initial treatment with a base such as lithium bis-trimethylsilylamide followed by treatment with $R_4\text{Hal}$ (7) such as the corresponding alkyl halides, sulfonyl halides/anhydrides, acyl halides/anhydrides and alkyl chloroformates and the like to afford 8. Removal of the acetonide group and saponification as described above affords compounds of the formula 1c. 1c can be converted to the free acid 1c' by treating the salt 1c with an acid, preferably a mineral acid, such as HCl or H_2SO_4 .

Alternatively, compound 4 can be converted directly to compound 8 by treatment with a preassembled amine $\text{R}_3\text{R}_4\text{NH}$ (compound 5b) and a base such as lithium bistrimethylsilylamide and the like in THF or DMF. Removal of the acetonide group and saponification as described above affords compounds of the formula 1c.

Alternatively, compounds of formula 1c can be prepared from intermediates 1 or 3 as outlined in Scheme 1.

Alternatively, compounds 6 or 8 can be converted to the lactones Id or Ie, respectively, by reaction with an acid such as trifluoroacetic acid in methylene chloride or chloroform which can be converted to the compounds of formula I (compounds Ib or Ic) by treatment with aqueous sodium hydroxide (Scheme 2).

5

SCHEME 2

- 10 Certain compounds of the formula I where $X = CR_5$ can be prepared from the previously known intermediate 9 (Huebsch, Walter et al. Ger. Offen. (1992), DE 4023308; Huebsch, Walter et al. Eur. Pat. Appl. (1992), EP 465970) as described in Scheme 3. Lithium aluminum hydride reduction of 9 affords the benzylic alcohol 10 which can be further reduced to give 11 ($R_5 = \text{methyl}$) using palladium on carbon under
- 15 hydrogen in the presence of trifluoroacetic acid in ethanol. Other intermediates containing R_5 groups as described for formula I may be prepared from intermediate 10

or its protected analogs using common transformations known in the art, for example, oxidation, alkylation, displacement, addition and the like.

The aminopyridine 11 may be converted to the fluoropyridine 12 by treatment with sodium nitrite and tetrafluoroboric acid in water. Treatment of 12 with a
5 heterocyclic amine R_3NH_2 (compound 5a) in the presence of a base such as lithium, sodium or potassium bistrimethylsilylamide in THF or DMF affords 13. Compound 13 can be converted to the alcohol 14 via reduction with a hydride reducing agent such as DIBAL. Oxidation of the alcohol 14 to the aldehyde 15 may be accomplished by using NaOCl in the presence of catalytic amounts of KBr and TEMPO in EtOAc or
10 methylene chloride or by using Dess-Martin's periodinane in methylene chloride. Treatment of 15 with BOC anhydride in the presence of DMAP affords compound 16 which may be converted to the olefin 17 via treatment with the sulfone 5 (see Scheme 1) in the presence of a strong base such as lithium, sodium or potassium bistrimethylsilylamide. Treatment of 17 with an acid such as trifluoroacetic acid
15 (TFA) in solvents such as methylene chloride or chloroform affords the lactone If which can be converted to the corresponding salt Ig. Ig may be converted to the corresponding free acid by treating Ig with an acid such as HCl or H_2SO_4 .

Alternatively, compound 12 can be converted to 13a which can be converted to compounds of formula Ih where R_4 is other than H via reduction, oxidation,
20 olefination and deprotection.

Certain compounds of formulae If, Ig and Ih (where $R_5 = H$) can also be prepared from compound 9 via selective hydrolysis of the sterically less hindered ethyl ester followed by decarboxylation of the resulting acid 9a using methods and reagents known in the art (e.g. heating with Cu powder/quinoline, U.S., 4405552, 20 Sep.
25 1983). The resulting intermediate 9b can be used to synthesize compounds of formulae If, Ig or Ih (where $R_5 = H$) in a manner described for intermediate 11.


Certain compounds of formula I where $X = CR_5$ and R_5 is alkoxyalkyl (i.e. compounds of formula Ii) can also be prepared from compound 9 as outlined in Scheme 3. Thus, conversion of the amino group of 9 to a fluoro group can be
30 achieved by using sodium nitrite and tetrafluoroboric acid to afford 9c. Coupling of 9c with 5b can afford 9d which can be reduced using diborane to give the alcohol 9e. Treatment of 9e with alkyl halides, alkyl triflates and the like under basic conditions

(NaH, LiH and the like) in THF or DMF can afford 9f. Conversion of 9f to the compounds of formula Ii can be carried out via reduction, oxidation, olefination and deprotection as described before.

Certain compounds of formula I where --- is $-\text{CH}_2\text{CH}_2-$ can be prepared from the corresponding unsaturated intermediates or other unsaturated compounds of formula I (where --- is ---) via catalytic hydrogenation followed by treatment with acids and/or aqueous base as shown in Scheme 4.

5

SCHEME 4



10

Compounds containing dihydroxy acid HMG-CoA binding domain side chains may be prepared in homochiral form, which is preferred, or may be prepared as racemic mixtures (3S^* , 5R^*) and may later be resolved to obtain the 3S , 5R isomer.

The following intermediates are novel compounds and form part of the present invention:


intermediates 1b, 1c, 2 to 4, 6, 8, 9a to 9f, 13a, 14a, 15a, 17a and 11 to 19
which may be represented by the following formulae:

A.




5

where R_1 and R_2 are the same or different and are independently selected from alkyl, alkoxyalkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl or cycloheteroalkyl; and



B.




15 where R_1 and R_2 are as defined above,


R_3 is aryl, heteroaryl, cycloalkyl or heterocycloalkyl;

R_4 is H, alkyl, cycloalkyl, haloalkyl, alkoxyalkyl, alkylthioalkyl, alkylsulfonyl, arylsulfonyl, alkoxycarbonyl, aryloxy carbonyl, heteroaryloxy carbonyl, alkylaminocarbonyl, arylaminocarbonyl, heteroarylamino carbonyl, alkylaminosulfonyl, acyl, arylcarbonyl, heteroarylcarbonyl or heteroarylsulfonyl; and

20




C.






5

where R₁ and R₂ are as defined above, and Q₂ is H₂N, F, R₃HN-, or R₃R₄N-,
R₅ is -COOH, lower alkyl, H, COOalkyl, -CH₂OH or alkylO-.


D.



10

where R₁, R₂ and R₅ are as defined above and Q₃ is R₃HN-, R₃R₄N-, ,
(where PG is a protecting group such as Boc () or Teoc (), and Q₄ is -COOalkyl, -CH₂OH or -CHO or

15



The compounds of the invention are inhibitors of 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase and thus are useful in inhibiting cholesterol

biosynthesis and/or in lowering triglycerides, in a manner similar to atorvastatin, pravastatin, simvastatin, lovastatin, cerivastatin, rosuvastatin, fluvastatin, pitavastatin, and the like.

5 A further aspect of the present invention is a pharmaceutical composition containing at least one of the compounds of formula I of the present invention in association with a pharmaceutical vehicle or diluent. The pharmaceutical composition can be formulated employing conventional solid or liquid vehicles of diluents and pharmaceutical additives of a type appropriate to the mode of desired administration. The compounds can be administered by an oral route, for example, in the form of
10 tablets, capsules, granules or powders, or they can be administered by a parenteral route in the form of injectable preparations. Such dosage forms contain from 0.1 to 1500 mg of active compound per dosage, for use in the treatment. The dose to be administered depends on the unitary dose, the symptoms, and the age and the body weight of the patient.

15 The compounds of the present invention can be administered in a similar manner as known compounds suggested for use in inhibiting cholesterol biosynthesis, such as pravastatin, lovastatin, simvastatin, rosuvastatin, atorvastatin, cerivastatin, fluvastatin, pitavastatin, and the like, in mammalian species such as humans, dogs, cats and the like. Thus, the compounds of the invention may be administered in an
20 amount from about 0.1 to 500 mg in a single dose or in the form of individual doses from 1 to 4 times per day, preferably 0.5 to 200 mg daily or in sustained release form.

The HMG CoA reductase inhibitors of formula I may be employed in combination with all therapeutic agents which are useful in combination with HMG CoA reductase inhibitors.

25 Thus, where desired, the compounds of structure I may be used in combination with one or more hypolipidemic agents or lipid-lowering agents, or lipid agents, or lipid modulating agents, and/or one or more other types of therapeutic agents including antidiabetic agents, anti-obesity agents, antihypertensive agents, platelet aggregation inhibitors, anti-Alzheimer's agents, anti-dementia agents, anti-
30 osteoporosis agents, and/or hormone replacement therapeutic agents, and/or other therapeutic agents, and/or other cardiovascular agents (including anti-anginal agents, anti-arrhythmic agents, anti-atherosclerosis agents, anti-inflammatory agents, anti-

platelet agents, anti-heart failure agents), anti-cancer agents, anti-infective agents, hormone replacement agents, growth hormone secretagogues, selective androgen receptor modulators (SARMs), and/or other therapeutic agents which may be administered orally in the same dosage form or in a separate oral dosage form, or by
5 injection.


The hypolipidemic agent or lipid-lowering agent or other lipid agent or lipid modulating agent which may be optionally employed in combination with the compounds of formula I of the invention may include 1,2,3 or more MTP inhibitors, HMG CoA reductase inhibitors, squalene synthetase inhibitors, PPAR α agonists,
10 PPAR dual α/γ agonists, PPAR δ agonists, fibric acid derivatives, ACAT inhibitors, lipoxxygenase inhibitors, cholesterol absorption inhibitors, ileal Na^+ /bile acid cotransporter inhibitors, upregulators of LDL receptor activity, cholesteryl ester transfer protein inhibitors, bile acid sequestrants, and/or nicotinic acid and derivatives thereof.

15 MTP inhibitors employed herein include MTP inhibitors disclosed in U.S. Patent No. 5,595,872, U.S. Patent No. 5,739,135, U.S. Patent No. 5,712,279, U.S. Patent No. 5,760,246, U.S. Patent No. 5,827,875, U.S. Patent No. 5,885,983 and U.S. Patent No. 5,962,440. Preferred are each of the preferred MTP inhibitors disclosed in each of the above patents and applications.

20 All of the above U.S. Patents and applications are incorporated herein by reference.

Most preferred MTP inhibitors to be employed in accordance with the present invention include preferred MTP inhibitors as set out in U.S. Patent Nos. 5,739,135 and 5,712,279, and U.S. Patent No. 5,760,246.

25 The most preferred MTP inhibitor is 9-[4-[4-[[2-(2,2,2-Trifluoroethoxy)benzoyl]amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)-9H-fluorene-9-carboxamide



The squalene synthetase inhibitors suitable for use herein include, but are not limited to, α -phosphono-sulfonates disclosed in U.S. Patent No. 5,712,396, those disclosed by Biller et al, J. Med. Chem., 1988, Vol. 31, No. 10, pp 1869-1871, including isoprenoid (phosphinyl-methyl)phosphonates as well as other known squalene synthetase inhibitors, for example, as disclosed in U.S. Patent No. 4,871,721 and 4,924,024 and in Biller, S.A., Neuenschwander, K., Ponpipom, M.M., and Poulter, C.D., Current Pharmaceutical Design, 2, 1-40 (1996).

In addition, other squalene synthetase inhibitors suitable for use herein include the terpenoid pyrophosphates disclosed by P. Ortiz de Montellano et al, J. Med. Chem., 1977, 20, 243-249, the farnesyl diphosphate analog A and presqualene pyrophosphate (PSQ-PP) analogs as disclosed by Corey and Volante, J. Am. Chem. Soc., 1976, 98, 1291-1293, phosphinylphosphonates reported by McClard, R.W. et al, J.A.C.S., 1987, 109, 5544 and cyclopropanes reported by Capson, T.L., PhD dissertation, June, 1987, Dept. Med. Chem. U of Utah, Abstract, Table of Contents, pp 16, 17, 40-43, 48-51, Summary.

Other hypolipidemic agents suitable for use herein include, but are not limited to, fibric acid derivatives, such as fenofibrate, gemfibrozil, clofibrate, bezafibrate, ciprofibrate, clinofibrate and the like, probucol, and related compounds as disclosed in U.S. Patent No. 3,674,836, fenofibrate, probucol and gemfibrozil being preferred, bile acid sequestrants such as cholestyramine, colestipol and DEAE-Sephadex (Secholex®, Policexide®) and cholestagel (Sankyo/Geltex), as well as lipostabil (Rhone-Poulenc), Eisai E-5050 (an N-substituted ethanolamine derivative), imanixil (HOE-402), tetrahydrolipstatin (THL), istigmastanylphosphorylcholine (SPC, Roche), aminocyclodextrin (Tanabe Seiyoku), Ajinomoto AJ-814 (azulene

derivative), melinamide (Sumitomo), Sandoz 58-035, American Cyanamid CL-277,082 and CL-283,546 (disubstituted urea derivatives), nicotinic acid (ER niacin, Niaspan), acipimox, acifran, neomycin, p-aminosalicylic acid, aspirin, poly(diallylmethylamine) derivatives such as disclosed in U.S. Patent No. 4,759,923, 5 quaternary amine poly(diallyldimethylammonium chloride) and ionenes such as disclosed in U.S. Patent No. 4,027,009, and other known serum cholesterol lowering agents.

The other hypolipidemic agent may be an ACAT inhibitor (which also has anti-atherosclerosis activity) such as disclosed in, Drugs of the Future 24, 9-15 (1999), 10 (Avasimibe); "The ACAT inhibitor, CI-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters", Nicolosi et al, Atherosclerosis (Shannon, Irel). (1998), 137(1), 77-85; "The pharmacological profile of FCE 27677: a novel ACAT inhibitor with potent hypolipidemic activity mediated by selective suppression of the hepatic secretion of ApoB100-containing lipoprotein", Ghiselli, 15 Giancarlo, Cardiovasc. Drug Rev. (1998), 16(1), 16-30; "RP.73163: a bioavailable alkylsulfinyl-diphenylimidazole ACAT inhibitor", Smith, C., et al, Bioorg. Med. Chem. Lett. (1996), 6(1), 47-50; "ACAT inhibitors: physiologic mechanisms for hypolipidemic and anti-atherosclerotic activities in experimental animals", Krause et al, Editor(s): Ruffolo, Robert R., Jr.; Hollinger, Manfred A., Inflammation: 20 Mediators Pathways (1995), 173-98, Publisher: CRC, Boca Raton, Fla.; "ACAT inhibitors: potential anti-atherosclerotic agents", Sliskovic et al, Curr. Med. Chem. (1994), 1(3), 204-25; "Inhibitors of acyl-CoA:cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. 6. The first water-soluble ACAT inhibitor with lipid-regulating activity. Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. 25 Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity", Stout et al, Chemtracts: Org. Chem. (1995), 8(6), 359-62, or TS-962 (Taisho Pharmaceutical Co. Ltd), as well as F-1394, CS-505, F-12511, HL-004, K-10085 and YIC-C8-434.

30 The hypolipidemic agent may be an upregulator of LDL receptor activity such as MD-700 (Taisho Pharmaceutical Co. Ltd) and LY295427 (Eli Lilly).

The hypolipidemic agent may be a cholesterol absorption inhibitor preferably Schering-Plough's SCH48461 (ezetimibe) as well as those disclosed in Atherosclerosis 115, 45-63 (1995) and J. Med. Chem. 41, 973 (1998).

5 The other lipid agent or lipid-modulating agent may be a cholesteryl transfer protein inhibitor (CETP) such as Pfizer's CP-529,414 (torcetrapib) as well as those disclosed in WO/0038722 and in EP 818448 (Bayer) and EP 992496, and Pharmacia's SC-744 and SC-795 as well as CETi-1 and JTT-705.

The hypolipidemic agent may be an ileal Na^+ /bile acid cotransporter inhibitor such as disclosed in Drugs of the Future, 24, 425-430 (1999).

10 The ATP citrate lyase inhibitor which may be employed in the combination of the invention may include, for example, those disclosed in U.S. Patent No. 5,447,954.

The other lipid agent also includes a phytoestrogen compound such as disclosed in WO 00/30665 including isolated soy bean protein, soy protein concentrate or soy flour as well as an isoflavone such as genistein, daidzein, glycitein or equol, or phytosterols, phytanol or tocotrienol as disclosed in WO 2000/015201;
15 a beta-lactam cholesterol absorption inhibitor such as disclosed in EP 675714;
an HDL upregulator such as an LXR agonist, a PPAR α -agonist and/or an FXR agonist;

an α -glucosidase inhibitor, an aldose reductase inhibitor and/or an LDL catabolism promoter such as disclosed in EP 1022272;
20 a sodium-proton exchange inhibitor such as disclosed in DE 19622222;
an LDL-receptor inducer or a steroidal glycoside such as disclosed in U.S. Patent No. 5,698,527 and GB 2304106;

an anti-oxidant such as beta-carotene, ascorbic acid, α -tocopherol or retinol as disclosed in WO 94/15592 as well as Vitamin C and an antihomocysteine agent such as folic acid, a folate, Vitamin B6, Vitamin B12 and Vitamin E;

25 isoniazid as disclosed in WO 97/35576;
a cholesterol absorption inhibitor, an HMG-CoA synthase inhibitor, or a lanosterol demethylase inhibitor as disclosed in WO 97/48701;
30 a PPAR δ agonist for treating dyslipidemia;
a PPAR α agonist for treating dyslipidemia;

a dual PPAR α/γ agonist such as muraglitazar (Bristol Myers-Squibb), tesaglitazar (AstraZeneca) or MK-767 (Merck/Kyorin/Banyu);

or a sterol regulating element binding protein-I (SREBP-1) as disclosed in WO 2000/050574, for example, a sphingolipid, such as ceramide, or neutral
5 sphingomyelase (N-SMase) or fragment thereof.

Preferred hypolipidemic agents are cholesterol absorption inhibitors such as ezetimibe, cholesterol ester transfer protein (CETP) inhibitors such as torcetrapib and JTT-705, dual PPAR α/δ agonists such as muraglitazar and tesaglitazar, as well as niacin and/or cholestagel.

10 The above-mentioned U.S. patents are incorporated herein by reference. The amounts and dosages employed will be as indicated in the Physician's Desk Reference and/or in the patents set out above or as otherwise known in the art.

The compounds of formula I of the invention will be employed in a weight ratio to the hypolipidemic agent (where present), within the range from about 500:1 to
15 about 1:500, preferably from about 100:1 to about 1:100.

The dose administered must be carefully adjusted according to age, weight and condition of the patient, as well as the route of administration, dosage form and regimen and the desired result.

The dosages and formulations for the hypolipidemic agent or other lipid agent
20 or lipid modulating agent will be as disclosed in the various patents and applications discussed above.

The dosages and formulations for the other hypolipidemic agent or other lipid agent or lipid modulating agent to be employed, where applicable, will be as set out in the latest edition of the Physicians' Desk Reference.

25 For oral administration, a satisfactory result may be obtained employing the MTP inhibitor in an amount within the range of from about 0.01 mg to about 500 mg and preferably from about 0.1 mg to about 100 mg, one to four times daily.

A preferred oral dosage form, such as tablets or capsules, will contain the MTP inhibitor in an amount of from about 1 to about 500 mg, preferably from about 2 to
30 about 400 mg, and more preferably from about 5 to about 250 mg, one to four times daily.

The squalene synthetase inhibitor may be employed in dosages in an amount within the range of from about 10 mg to about 2000 mg and preferably from about 25 mg to about 200 mg.

5 A preferred oral dosage form, such as tablets or capsules, will contain the HMG CoA reductase inhibitor in an amount from about 0.1 to about 200 mg, preferably from about 0.5 to about 80 mg, and more preferably from about 1 to about 40 mg.

10 A preferred oral dosage form, such as tablets or capsules will contain the squalene synthetase inhibitor in an amount of from about 10 to about 500 mg, preferably from about 25 to about 200 mg.

The anti-atherosclerotic agent includes a lipoxygenase inhibitor including a 15-lipoxygenase (15-LO) inhibitor such as benzimidazole derivatives as disclosed in WO 97/12615, 15-LO inhibitors as disclosed in WO 97/12613, isothiazolones as disclosed in WO 96/38144, and 15-LO inhibitors as disclosed by Sendobry et al
15 "Attenuation of diet-induced atherosclerosis in rabbits with a highly selective 15-lipoxygenase inhibitor lacking significant antioxidant properties," Brit. J. Pharmacology (1997) 120, 1199-1206, and Cornicelli et al, "15-Lipoxygenase and its Inhibition: A Novel Therapeutic Target for Vascular Disease", Current Pharmaceutical Design, 1999, 5, 11-20.

20 The compounds of formula I and the hypolipidemic agent may be employed together in the same oral dosage form or in separate oral dosage forms taken at the same time.

The compositions described above may be administered in the dosage forms as described above in single or divided doses of one to four times daily. It may be
25 advisable to start a patient on a low dose combination and work up gradually to a high dose combination.

The antidiabetic agent which may be optionally employed in combination with the HMG-CoA reductase inhibitor of formula I may be 1,2,3 or more antidiabetic agents or antihyperglycemic agents including insulin secretagogues or insulin
30 sensitizers, which may include biguanides, sulfonyl ureas, glucosidase inhibitors, aldose reductase inhibitors, PPAR γ agonists such as thiazolidinediones, PPAR α agonists (such as fibric acid derivatives), PPAR δ antagonists or agonists, aP2

inhibitors, PPAR α/γ dual agonists, dipeptidyl peptidase IV (DP4) inhibitors, SGLT2 inhibitors, glycogen phosphorylase inhibitors, and/or meglitinides, and/or glucagon-like peptide-1 (GLP-1), and/or a PTP-1B inhibitor (protein tyrosine phosphatase-1B inhibitor), as well as insulin and slow release insulin (Basulin™ (Flamel)).

- 5 The antidiabetic agent may be an oral antihyperglycemic agent preferably a biguanide such as metformin or phenformin or salts thereof, preferably metformin HCl.

Where the antidiabetic agent is a biguanide, the compounds of structure I will be employed in a weight ratio to biguanide within the range from about 0.001:1 to about 10:1, preferably from about 0.01:1 to about 5:1.

- 10 The antidiabetic agent may also preferably be a sulfonyl urea such as glyburide (also known as glibenclamide), glimepiride (disclosed in U.S. Patent No. 4,379,785), glipizide, gliclazide or chlorpropamide, other known sulfonylureas or other antihyperglycemic agents which act on the ATP-dependent channel of the β -cells, with glyburide and glipizide being preferred, which may be administered in the same or in separate oral dosage forms.

The compounds of structure I will be employed in a weight ratio to the sulfonyl urea in the range from about 0.01:1 to about 100:1, preferably from about 0.02:1 to about 5:1.

- 20 The oral antidiabetic agent may also be a glucosidase inhibitor such as acarbose (disclosed in U.S. Patent No. 4,904,769) or miglitol (disclosed in U.S. Patent No. 4,639,436), which may be administered in the same or in a separate oral dosage forms.

The compounds of structure I will be employed in a weight ratio to the glucosidase inhibitor within the range from about 0.01:1 to about 100:1, preferably from about 0.05:1 to about 10:1.

- 25 The compounds of structure I may be employed in combination with a PPAR γ agonist such as a thiazolidinedione oral anti-diabetic agent or other insulin sensitizers (which has an insulin sensitivity effect in NIDDM patients) such as troglitazone (Warner-Lambert's Rezulin®, disclosed in U.S. Patent No. 4,572,912), rosiglitazone (SKB), pioglitazone (Takeda), Mitsubishi's MCC-555 (disclosed in U.S. Patent No.
- 30

5,594,016), Glaxo-Welcome's GL-262570, englitazone (CP-68722, Pfizer) or darglitazone (CP-86325, Pfizer, isaglitazone (MIT/J&J), JTT-501 (JPNT/P&U), L-895645 (Merck), R-119702 (Sankyo/WL), NN-2344 (Dr. Reddy/NN), or YM-440 (Yamanouchi), preferably rosiglitazone and pioglitazone.

5 The compounds of structure I will be employed in a weight ratio to the thiazolidinedione in an amount within the range from about 0.01:1 to about 100:1, preferably from about 0.05:1 to about 10:1.

10 The sulfonyl urea and PPAR γ agonists in amounts of less than about 150 mg oral antidiabetic agent may be incorporated in a single tablet with the compounds of structure I.

15 The compounds of structure I may also be employed in combination with an antihyperglycemic agent such as insulin or slow release insulin (BasulinTM), or with glucagon-like peptide-1 (GLP-1) or mimetic such as GLP-1(1-36) amide, GLP-1(7-36) amide, GLP-1(7-37) (as disclosed in U.S. Patent No. 5,614,492 to Habener, the disclosure of which is incorporated herein by reference), as well as AC2993 (Amylin) and LY-315902 (Lilly), which may be administered via injection, intranasal, inhalation or by transdermal or buccal devices.

20 Where present, metformin, the sulfonyl ureas, such as glyburide, glimepiride, glipyrizide, glipizide, chlorpropamide and gliclazide and the glucosidase inhibitors acarbose or miglitol or insulin (injectable, pulmonary, buccal, or oral) may be employed in formulations as described above and in amounts and dosing as indicated in the Physician's Desk Reference (PDR).

25 Where present, metformin or salt thereof may be employed in amounts within the range from about 500 to about 2000 mg per day which may be administered in single or divided doses one to four times daily.

 Where present, the PPAR anti-diabetic agent may be employed in amounts within the range from about 0.01 to about 2000 mg/day which may be administered in single or divided doses one to four times per day.

30 Where present insulin and other anti-diabetic agents as set out above may be employed in formulations, amounts and dosing as indicated by the Physician's Desk Reference.

Where present GLP-1 peptides or mimetics may be administered in oral buccal formulations, by nasal administration or parenterally as described in U.S. Patent Nos. 5,346,701 (TheraTech), 5,614,492 and 5,631,224 which are incorporated herein by reference.

5 The antidiabetic agent or other lipid agent may also be a PPAR modulator such as a PPAR α/γ dual agonist such as tesaglitazar (Astra/Zeneca), muraglitazar (Bristol Myers-Squibb), MK-767 (Merck/Kyorin/Banyu), GW-409544 (Glaxo-Wellcome), KRP297 (Kyorin Merck) as well as those disclosed by Murakami et al, "A Novel Insulin Sensitizer Acts As a Coligand for Peroxisome Proliferation - Activated
10 Receptor Alpha (PPAR alpha) and PPAR gamma. Effect on PPAR alpha Activation on Abnormal Lipid Metabolism in Liver of Zucker Fatty Rats", Diabetes 47, 1841-1847 (1998), and in U.S. application Serial No. 09/664,598, filed September 18, 2000, (attorney file LA29) the disclosure of which is incorporated herein by reference, employing dosages as set out therein, which compounds designated as preferred are
15 preferred for use herein.

 The antidiabetic agent may be an SGLT2 inhibitor such as disclosed in U.S. Patents Nos. 6,414,126 and 6,515,117, employing dosages as set out therein. Preferred are the compounds designated as preferred in the above patents.

 The antidiabetic agent may be an $\alpha P2$ inhibitor such as disclosed in U.S. Patent
20 No. 6,548,529, employing dosages as set out herein. Preferred are the compounds designated as preferred in the above patent.

 The antidiabetic agent may be a DPP4 inhibitor such as disclosed in U.S. Patent No. 6,395,767, U.S. Patent No. 6,573,287, U.S. Patent No. 6,395,767 (BMS-477118 (preferred), BMS-471211 and BMS 538,305), WO99/38501, WO99/46272,
25 WO99/67279 (PROBIODRUG), WO99/67278 (PROBIODRUG), WO99/61431 (PROBIODRUG), NVP-LAF-237, NVP-DPP728A (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)-pyrrolidine) (Novartis) as disclosed by Hughes et al, Biochemistry, 38(36), 11597-11603, 1999, TSL-225 (tryptophyl-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid (disclosed by Yamada et al, Bioorg. & Med.
30 Chem. Lett. 8 (1998) 1537-1540, 2-cyanopyrrolidides and 4-cyanopyrrolidides as disclosed by Ashworth et al, Bioorg. & Med. Chem. Lett., Vol. 6, No. 22, pp 1163-1166 and 2745-2748 (1996) employing dosages as set out in the above references.

The meglitinide which may optionally be employed in combination with the compound of formula I of the invention may be repaglinide or Starlix® (Novartis), nateglinide (Novartis) or KAD1229 (PF/Kissei), with repaglinide being preferred.

5 The antidiabetic compound may be a melanocortin receptor agonist such as a spiroperidine as disclosed in WO 99/64002.

The HMG CoA reductase inhibitor of formula I will be employed in a weight ratio to the meglitinide, PPAR modulator such as a PPAR γ agonist, PPAR α agonist, PPAR δ agonists or antagonist, PPAR α/γ dual agonist, aP2 inhibitor, DP4 inhibitor or SGLT2 inhibitor or other antidiabetic agent within the range from about 0.01:1 to
10 about 100:1, preferably from about 0.05:1 to about 10:1.

The other type of therapeutic agent which may be optionally employed with the HMG CoA reductase inhibitor of formula I may be 1, 2, 3 or more of an anti-obesity agent including a beta 3 adrenergic agonist, a lipase inhibitor, a serotonin and/or dopamine modulator/mimic, norepinephrine (NE) modulator/mimic, an aP2
15 inhibitor, a thyroid receptor beta drug, a PTP-1B inhibitor, an anorectic agent, a PPAR modulator including PPAR γ antagonists, PPAR α agonists, PPAR δ antagonists, a CCKA agonist, a leptin inhibitor such as a leptin receptor activator, a neuropeptide Y antagonist, a melanocortin-4-receptor (MC4R) agonist, a CB-1 inverse agonist, a fatty acid oxidation upregulator or inducer (such as Famoxin® Genset), a 5-HT_{2c} agonist,
20 and an acetyl CoA carboxylase (ACC) inhibitor.

The beta 3 adrenergic agonist which may be optionally employed in combination with a compound of formula I may be AJ9677 (Takeda/Dainippon), L750355 (Merck), or CP331648 (Pfizer) or other known beta 3 agonists as disclosed in U.S. Patent Nos. 5,541,204, 5,770,615, 5,491,134, 5,776,983 and 5,488,064, with
25 AJ9677, L750,355 and CP331648 being preferred.

The neuropeptide Y antagonists which may be optionally employed in combination with a compound of formula I include those described in WO 0113917 (BMS) or in U.S. Patent No. 6,218,408 (Synaptic) and in WO 0114376 (Banyu).

The lipase inhibitor which may be optionally employed in combination with a
30 compound of formula I may be orlistat or ATL-962 (Alizyme), with orlistat being preferred.

The serotonin and dopoamine modulator/mimic and/or norepinephrine modulator/mimic which may be optionally employed in combination with a compound of formula I may be sibutramine.

5 The anorectic agent which may be optionally employed in combination with a compound of formula I may be topiramate, Axokine® (Regeneron) (analogue of Ciliary Neurotrophic Factor) dexamphetamine, phentermine, phenylpropanolamine or mazindol, with dexamphetamine or topiramate being preferred.

10 The thyroid receptor beta compound which may be optionally employed in combination with a compound of formula I may be a thyroid receptor ligand as disclosed in WO97/21993 (U. Cal SF), WO99/00353 (KaroBio), GB98/284425 (KaroBio), and U.S. Provisional Application 60/183,223 filed February 17, 2000, with compounds of the KaroBio applications and the above U.S. provisional application being preferred.

15 Examples of the ACC inhibitors which may be employed include those described in WO 03/072197.

Examples of the CB-1 inverse agonists which may be employed include SR-141716 (Sanofi) and FLV-319 (Folvay).

Examples of the 5-HT_{2c} agonists which may be employed include compounds as disclosed in WO 00/77010.

20 The CCKA agonists which may be employed herein include Glaxo-SmithKline's GI-181,771 and Sanofi's SR146,131.

The PTP-1B inhibitor which may be an anti-obesity and/or an antidiabetic agent include those disclosed in WO 99/585,521, WO 99/58518, WO 99/58522 and WO 99/61435.

25 The anti-obesity agent employed may also be Pfizer's P57 or CP-644,673 (licensed from Phytopharm).

The various anti-obesity agents described above may be employed in the same dosage form with the compound of formula I or in different dosage forms, in dosages and regimens as generally known in the art or in the PDR.

30 The antihypertensive agents which may be employed in combination with the HMG CoA reductase inhibitors of the invention include ACE inhibitors, angiotensin II receptor antagonists, MR agonist, NEP inhibitors such as candoxatril, NEP/ACE

inhibitors, as well as calcium channel blockers (such as verapamil and amlodipine besylate), T-channel calcium antagonists (such as mibefradil), β -adrenergic blockers, diuretics, α -adrenergic blockers (such as doxazosin mesylate and terazosin HCl), dual action receptor antagonists (DARA), heart failure drugs such as digoxin, and other
5 types of antihypertensive agents.

The angiotensin converting enzyme inhibitor which may be employed herein includes those containing a mercapto (-S-) moiety such as substituted proline derivatives, such as any of those disclosed in U.S. Pat. No. 4,046,889 to Ondetti et al mentioned above, with captopril, that is, 1-[(2S)-3-mercapto-2-methylpropionyl]-L-
10 proline, being preferred, and mercaptoacyl derivatives of substituted prolines such as any of those disclosed in U.S. Pat. No. 4,316,906 with zofenopril being preferred.

Other examples of mercapto containing ACE inhibitors that may be employed herein include rentiapril (fentiapril, Santen) disclosed in Clin. Exp. Pharmacol. Physiol. 10:131 (1983); as well as pivopril and YS980.

15 Other examples of angiotensin converting enzyme inhibitors which may be employed herein include any of those disclosed in U.S. Pat. No. 4,374,829 mentioned above, with N-(1-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-L-proline, that is, enalapril, being preferred, any of the phosphonate substituted amino or imino acids or salts disclosed in U.S. Pat. No. 4,452,790 with (S)-1-[6-amino-2-[[hydroxy-(4-
20 phenylbutyl)phosphinyl]oxy]-1-oxohexyl]-L-proline or (ceronapril) being preferred, phosphinylalkanoyl prolines disclosed in U.S. Pat. No. 4,168,267 mentioned above with fosinopril being preferred, any of the phosphinylalkanoyl substituted prolines disclosed in U.S. Pat. No. 4,337,201, and the phosphonamidates disclosed in U.S. Pat. No. 4,432,971 discussed above.

25 Preferred ACE inhibitors are captopril, fosinopril, enalapril, lisinopril, cetapril, cilazapril, indalapril, spirapril, perindopril, ceranapril, quinapril, benazepril, fentiapril, ramipril and moexipril.

NEP/ACE inhibitors may also be employed herein in that they possess neutral endopeptidase (NEP) inhibitory activity and angiotensin converting enzyme (ACE)
30 inhibitory activity. Examples of NEP/ACE inhibitors suitable for use herein include those disclosed in U.S. Pat. No.s. 5,362,727, 5,366,973, 5,225,401, 4,722,810, 5,223,516, 4,749,688, U.S. Patent. No. 5,552,397, U.S. Pat. No. 5,504,080, U.S.

Patent No. 5,612,359, U.S. Pat. No. 5,525,723, European Patent Application 0599,444, 0481,522, 0599,444, 0595,610, European Patent Application 0534363A2, 534,396 and 534,492, and European Patent Application 0629627A2.

Preferred are those NEP/ACE inhibitors and dosages thereof which are
5 designated as preferred in the above patents/applications which U.S. patents are incorporated herein by reference; most preferred are omapatrilat, gemopatrilat ([S[(R*,R*)]-hexahydro-6-[(2-mercapto-1-oxo-3-phenylpropyl)amino]-2,2-dimethyl-7-oxo-1H-azepine-1-acetic acid) and CGS 30440.

The angiotensin II receptor antagonist (also referred to herein as angiotensin II
10 antagonist or AII antagonist) suitable for use herein includes, but is not limited to, irbesartan, losartan, valsartan, candesartan, tasosartan or eprosartan, with irbesartan, losartan or valsartan being preferred.

A preferred oral dosage form, such as tablets or capsules, will contain the ACE
inhibitor or AII antagonist in an amount within the range from about 0.1 to about 500
15 mg, preferably from about 5 to about 200 mg and more preferably from about 10 to about 150 mg.

It will be appreciated that preferred dosages of ACE inhibitor and AII
antagonist will be as set out in the latest edition of the Physician's Desk Reference (PDR).

20 Dual action receptor antagonists (DARA) suitable for use herein include those disclosed in U.S. applications Serial No. 09/513,779, filed February 25, 2000, and Serial No. 09/604,322, filed June 26, 2000.

Other examples of preferred antihypertensive agents suitable for use herein
include omapatrilat (Vanlev®), gemopatrilat, amlodipine besylate (Norvasc®),
25 prazosin HCl (Minipress®), verapamil, nifedipine, diltiazem, felodipine, nisoldipine, isradipine, nicardipine, beta blockers such as nadolol, atenolol (Tenormin®), sotalol, terazosin, doxazosin, carvedilol, and propranolol, and clonidine HCl (Catapres®).

Diuretics which may be employed in combination with compounds of formula
I include hydrochlorothiazide, torasemide, furosemide, spironolactone, and
30 indapamide.

Antiplatelet agents which may be employed in combination with compounds of formula I of the invention include aspirin, clopidogrel, ticlopidine, dipyridamole, CS-747, (Lilly), abciximab, tirofiban, eptifibatide, anagrelide, and ifetroban, with clopidogrel and aspirin being preferred.

- 5 Anti-thrombotic agents which may be employed in combination with compounds of formula I of the invention include melagatran and ximelagatran (Exanta™ Astra Zeneca), warfarin and Factor Xa inhibitors such as razaxaban.

10 The antihypertensive agents, diuretics and antiplatelet drugs may be employed in amounts as indicated in the PDR. Ifetroban may be employed in amounts as set out in U.S. Patent No. 5,100,889.

 Anti-Alzheimer's agents or anti-dementia agents suitable for use herein with the HMG CoA reductase inhibitors of the invention include tacrine HCl (Cognex®) and donepezil (Aricept®), as well as γ -secretase inhibitors, β -secretase inhibitors and/or antihypertensive agents. Dosages employed will be as set out in the PDR.

- 15 Antiosteoporosis agents suitable for use herein in combination with the HMG CoA reductase inhibitors of the invention include parathyroid hormone or bisphosphonates, such as MK-217 (alendronate) (Fosamax®) as well as Ca receptor agonists and progestin receptor agonists. Dosages employed will be as set out in the PDR.

20 The hormone replacement therapeutic agents, where present, will be employed in dosages as set out in the latest edition of the PDR. Examples of such agents include selective estrogen receptor modulators (SERMs) such as raloxifen, tamoxifen or lasoxifen.

 The HMG CoA reductase compound of the invention may also be employed in
25 combination with a tyrosine kinase inhibitor such as disclosed in WO 2000/053605;
 the selective androgen receptor modulator (SARM) suitable for use herein may be LGD-2226 (Ligand) or those compounds disclosed in WO 03/011824.

 the antiarrhythmic agents suitable for use herein include β -blockers as set out herein including sotalol and amioderome, calcium channel blockers as set out herein
30 including verapamil, nifedipine, amlodipine-besylate, and diltiazem, which may also be used in combination with a debrillator device such as a pace maker;

coenzyme Q sub. 10 such as disclosed in U.S. Patent No. 5,316,765,
4,933,165, 4,929,437;

an agent that upregulates type III endothelial cell nitric acid syntase such as
disclosed in WO 2000/003746;

5 a chondroprotective compound such as a polysulfated glycosaminoglycan
(PSGAG), glucosamine, chondroitin sulfate (CS), hyaluronic acid (HA), pentosan
polysulfate (PPS), doxycycline or minocycline, such as disclosed in EP 970694;

a cyclooxygenase (COX)-2 inhibitor, such as celecoxib (Celebrex® (Searle))
or rofecoxib (Vioxx® (Merck)) or a glycoprotein IIa/IIIb receptor antagonist such as
10 disclosed in WO 99/45913 and tirofiban or abciximab;

a 5-HT reuptake inhibitor such as disclosed in WO 99/44609;

anti-anginal agents such as vasodilators, for example, isosorbide dinitrate, or
nitroglycerin;

a growth hormone secretagogue such as disclosed in U.S. applications Serial
15 No. 09/662,448, filed September 14, 2000, and U.S. Provisional application
60/203,335, filed May 11, 2000, and MK-677 (Merck), Pfizer's CP-424391 and
Lilly's LY 444,711;

anti-atherosclerosis agents such as ACAT inhibitors and lipoxxygenase
inhibitors as described herein and phospholipase inhibitors;

20 anti-infective agents such as quinolones, for example, ciprofloxacin, ofloxacin,
and Tequin® (Bristol-Myers Squibb), macrolides such as erythromycin and
clarithromycin (Biaxin® (Abbott)), and azithromycin (Zithromax (Pfizer)); or

an immunosuppressant (for use in transplantations) such as cyclosporine,
mycophenolate mofetil, azathioprine and the like.

25 As used herein, the phrase "antineoplastic agent" refers to compounds which
prevent cancer cells from multiplying. In general, the antineoplastic agents used
herein prevent cancer cells from multiplying by: (1) interfering with the cell's ability
to replicate DNA, or (2) inducing apoptosis in the cancerous cells.

Examples of antineoplastic agents which are suitable for use in combinations
30 of this invention include, but are not limited to, microtubule-stabilizing agents such as
the taxanes, for example, paclitaxel (also known as Taxol®), docetaxel (also known

as Taxotere®), 7-O-methylthio- methylpaclitaxel (disclosed in U.S. 5,646,176), 3'-*tert*-butyl-3'-N-*tert*-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-N-debenzoyl-4-O-methoxycarbonyl-paclitaxel (disclosed in USSN 60/179,965 filed on February 3, 2000, and example 17 herein), C-4 methyl carbonate paclitaxel (disclosed in WO 94/14787), the epothilone, such as epothilone A, epothilone B, epothilone C, epothilone D, desoxyepothilone A, desoxyepothilone B, [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4-aza-17-oxabicyclo[14.1.0]hepta-decane-5,9-dione (disclosed in WO 99/02514), [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-(aminomethyl)-4-thiazolyl]-1-methylethenyl]-7,11-di-hydroxy-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]-heptadecane-5,9-dione (disclosed in USSN 09/506,481 filed on February 17, 2000, and examples 7 and 8 herein), and derivatives thereof; microtubule-disruptor agents; alkylating agents; anti-metabolites; epidophyllotoxin; an antineoplastic enzyme; a topoisomerase inhibitor; procarbazine; mitoxantrone; platinum coordination complexes; biological response modifiers; growth inhibitors; hormonal/antihormonal therapeutic agents; and haematopoietic growth factors.

Other classes of antineoplastic agents suitable for use in the method of the present invention include, but are not limited to, the anthracycline family of drugs, the vinca drugs, the mitomycins, the bleomycins, the cytotoxic nucleosides, discodermolide, the pteridine family of drugs, diynenes, aromatase inhibitors, and the podophyllotoxins. Particularly useful members of those classes not previously mentioned include, for example, doxorubicin, carminomycin, daunorubicin, aminopterin, methotrexate, methopterin, dichloro-methotrexate, mitomycin C, porfiromycin, 5-fluorouracil, 6-mercaptopurine, gemcitabine, cytosine arabinoside, podophyllotoxin or podophyllotoxin derivatives such as etoposide, etoposide phosphate or teniposide, melphalan, vinblastine, vincristine, leurosine, vindesine, leurosine, and the like. Other useful antineoplastic agents include estramustine, cisplatin, carboplatin, cyclophosphamide, bleomycin, tamoxifen, ifosfamide, melphalan, hexamethyl melamine, thiotepa, cytarabin, idatrexate, trimetrexate, dacarbazine, L-asparaginase, camptothecin, CPT-11, topotecan, ara-C, bicalutamide, flutamide, leuprolide, pyridobenzoindole derivatives, interferons, and interleukins.

It will be appreciated that unless otherwise specified the dosage regiment for therapeutic agents used in combination with the compounds of the invention will be as specified in the PDR.

In carrying out the method of the invention for treating hypercholesterolemia, hyperlipidemia, hyperlipoproteinemia, hypertriglyceridemia, or atherosclerosis, and related diseases, or Alzheimer's disease or osteoporosis, or other disclosures as set out hereinbefore, a pharmaceutical composition will be employed containing the compounds of structure I, with or without other cholesterol lowering agents, osteoporosis agents, Alzheimer's agents, antidiabetic agent(s) and/or antihyperlipidemic agent(s) and/or other type therapeutic agents in association with a pharmaceutical vehicle or diluent. The pharmaceutical composition can be formulated employing conventional solid or liquid vehicles or diluents and pharmaceutical additives of a type appropriate to the mode of desired administration, such as pharmaceutically acceptable carriers, excipients, binders and the like. The compounds can be administered to mammalian species including humans, monkeys, dogs, etc. by an oral route, for example, in the form of tablets, capsules, beads, granules or powders, or they can be administered by a parenteral route in the form of injectable preparations, or they can be administered intranasally or in transdermal patches. Typical solid formulations will contain from about 0.1 to about 500 mg of a compound of formula I. The dose for adults is preferably between 0.5 and 1,000 mg per day, which can be administered in a single dose or in the form of individual doses from 1-4 times per day and also single dose once weekly (5 to 1000 mg).

A typical injectable preparation is produced by aseptically placing 250 mg of compounds of structure I into a vial, aseptically freeze-drying and sealing. For use, the contents of the vial are mixed with 2 mL of physiological saline, to produce an injectable preparation.

The following abbreviations are employed in the Examples and elsewhere herein:

μL = microliter
AcCN = acetonitrile
aq. = aqueous
Bn = benzyl


- Boc = tert-butoxycarbonyl
bp = boiling point
Cbz = carbobenzyloxy or carbobenzoxy or benzyloxycarbonyl
DEAD = diethyl azodicarboxylate
- 5 Dess-Martins's periodinane = 1,1,1-tris(acetyloxy)-1,1-dihydro-1,2-benziodoxol-3-(1H)-one
DI water = dionized water
DIBAL = diisobutylaluminum hydride
DIPEA = diisopropyl ethylamine
- 10 DMPU = 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone
EDAC = 3-ethyl-3'-(dimethylamino)propyl-carbodiimide hydrochloride (or 1-[(3-(dimethylamino)propyl)]-3-ethylcarbodiimide hydrochloride)
Et = ethyl
Et₂NH = diethylamine
- 15 FMOC = fluorenylmethyloxycarbonyl
g = gram(s)
h or hr = hour(s)
HOAc or AcOH = acetic acid
HOAT = 1-hydroxy-7-azabenzotriazole
- 20 HOBT or HOBT.H₂O = 1 hydroxybenzotriazole hydrate
HPLC = high performance liquid chromatography
i-BU = iso-butyl
L = liter
LC/MS = high performance liquid chromatography/mass spectrometry
- 25 LDA = lithium diisopropylamide
LiHDMS = lithium bis(trimethylsilyl)amide
LiN(TMS) = Libis(trimethylsilyl)amide
MCPMA – m-chloro-p-benzoic acid
Me = methyl
- 30 meq = milliequivalent
mg = milligram(s)
min = minute(s)

- mL = milliliter
mmol = millimole(s)
mol = moles
mp = melting point
- 5 MS or Mass Spec = mass spectrometry
MTBE = methyl t-butyl ether
NaHMDS = sodium bis(trimethylsilyl)amide
n-BuLi = n-butyllithium
NMM = N-methyl morpholine
- 10 NMO = methylmorpholine N-oxide
NMR = nuclear magnetic resonance
Pd/C = palladium on carbon
Ph = phenyl
PPh₃ = triphenylphosphine
- 15 PtO₂ = platinum oxide
PTSH = N-phenylthiotetrazole
PyBOP reagent = benzotriazol-1-yloxy-tripyrrolidino phosphonium
hexafluorophosphate
Red-AL = sodium bis(2-methoxyethoxy)aluminum hydride
- 20 RT, rt = room temperature
sat or sat'd = saturated
TEA = triethylamine
TEMPO = 2,2,6,6-tetramethyl-1-piperidinyloxy free radical
TFA = trifluoroacetic acid
- 25 TLC = thin layer chromatography
TMS = trimethylsilyl
TPAP = tetrapropylammonium perruthenate


EXAMPLES

The following Examples represent preferred embodiments of the invention. Compound names cited in the examples, unless otherwise indicated, can be converted to structure drawings using the AutoNom (v 2.1) feature in ChemDraw Ultra v 6.0.4.

5


EXAMPLE 1

10 A.



This compound was prepared according to the procedure reported by Masamichi Watanabe et al. (Bioorganic & Medicinal Chemistry (1997), 5(2), 437-444; Eur. Pat. Appl. 1993, 18 pp. EP 521471).


B.



To a solution of the compound from part A (3.7g, 10.1 mmol) in 100mL toluene at -70°C was added DIBAL (1M in methylene chloride, 25 mL, 25 mmol) dropwise. After stirring at -70°C for 0.5h, the reaction mixture was quenched by carefully adding saturated ammonium chloride solution and stirred at RT for 0.5 h.

- 5 The organic layer was separated, dried over MgSO_4 , concentrated, and the crude product thus obtained was subjected to flash chromatography (silica gel/hexane-EtOAc 80:20 to 20:80 gradient to afford the title compound as a white solid (2g, 61% yield).


10 C.




- To a solution of the title compound of part B (2g, 6.2 mmol), TEMPO free radical (Aldrich Chemical Co., 10mg) and KBr (73mg) in 20 mL EtOAc at 0°C was added a solution of buffered bleach (ca. 0.9M, adjusted to pH 9.4 by the addition of solid sodium bicarbonate) dropwise with stirring over 0.5h. The mixture was sequentially washed with ½ saturated sodium thiosulfate, 1N NaOH and brine. The organic layer was dried (MgSO_4) and concentrated to afford the title compound 1.98g (crude yield 99%).

20

D.




To a solution of the title compound of part C (1.98g, 6.1 mmol) and



- 5 (Brodfehrer, Paul R. et al. PCT Int. Appl. (2002), WO 0298854, 2.79 g, 6.1 mmol) in 25 mL THF at -78°C was added with stirring a solution of lithium bistrimethylsilylamide (1M in THF, 7.75 mL, 7.75 mmol) dropwise. After 15 min. at -78°C the mixture was quenched by adding sat. NaHCO_3 , extracted with EtOAc, dried (MgSO_4), concentrated and the crude product was purified by flash chromatography
- 10 (silica gel/hexane EtOAc 100:0 to 50:50 gradient) to afford 1.1g of the title compound as a pale foamy solid.

E.




15

- Lithium bis(trimethylsilyl)amide (1.0 M in THF, 407 mL, 0.47 mol) was added over 65 min to a stirred solution of 2-methyl-2H-[1,2,4]triazol-3-ylamine (37.5 g, 0.37 mol, prepared as described by Barascut, Jean L. et al., Bull. Soc. Chim. Fr. (1973), (5) part 2, 1849-53) and iodomethane (66.6 mL, 1.11 mol) in THF (1.2 L)
- 20 under nitrogen at 0°C . After stirring at 0°C for 1.5 h, additional lithium bis(trimethylsilyl)amide (1.0 M in THF, 90 mL, 0.09 mol) was added over 10 min. After stirring for an additional 2.5 h, ^1H NMR of an aliquot indicated 9% starting material, 74% of the desired product (methyl-(2-methyl-2H-[1,2,4]triazol-3-yl)-amine), and 17% of trimethylated product (dimethyl-(2-methyl-2H-[1,2,4]triazol-3-

yl)-amine) and the reaction was quenched with water (~7 mL) and evaporated in vacuo. The white solid which had formed when the reaction volume had been reduced to 500 mL was filtered. The filtrate was then evaporated to afford 228 g of crude product. The crude product was chromatographed (alumina activity I/EtOAc-CH₂Cl₂) to afford 20.1 g (48%) methyl-(2-methyl-2H-[1,2,4]triazol-3-yl)-amine. ¹H NMR (CDCl₃) δ 7.40 (1 H, s), 4.71 (1 H, broad s), 3.48 (3 H, s), and 2.92 (3 H, d, J = 5.0 Hz). ¹³C NMR (CDCl₃) ppm 156.0, 147.8, 32.9, and 29.9.

To a stirred solution of methyl-(2-methyl-2H-[1,2,4]triazol-3-yl)-amine (prepared as described above, 51.5 g, 0.46 mol) in 1L THF at -60°C under nitrogen was added a solution of 1N lithium bis(trimethylsilyl)amide (480 mL, 0.48 mol) over 15 minutes. The mixture was allowed to come to 10°C and stirred for 15 minutes. The reaction mixture was cooled to -60°C, and the resulting slurry was transferred over 30 minutes to a stirred solution of the title compound of step D (200 g, 0.365 mol) in 1L THF at -60°C. The reaction mixture was allowed to come to -17°C over 1h, diluted with EtOAc and washed sequentially with sat. NaHCO₃ solution and brine. The organic layer was dried and concentrated and the crude product thus obtained was subjected to flash chromatography (silica gel/hexane-EtOAc 100:0 to 50:50 gradient) to afford 176 g of white solid. This material was recrystallized from MeOH-water to afford the title compound as a white solid (170 g).

F.




To a solution of the title compound prepared in a manner similar to that described in step E (234 g, 402.7 mmol) in 1L THF was added 1N HCL (403 mL). The reaction mixture was stirred at RT for 6h, then added a solution of NaOH (32.5 g) in 150 mL water followed by the addition of 100 mL methanol. The reaction mixture



was stirred for 1.5h at RT, diluted with water (200 mL) and extracted with EtOAc (3X500 mL). The aqueous layer was concentrated and the residue was subjected to reversed phase chromatography (C18 silica/water-acetonitrile 100:0 to 70:30) to afford the title compound as a white solid (166.8 g); analytical LC retention time = 3.30 minutes (YMC ODS S5 4.6 mm X 50 mm column/methanol-water-phosphoric acid 10:90:0.2 to 90:10:0.2 gradient over 4 minutes, 4 mL/min. flow rate); (M+H)⁺ 485 (carboxylic acid).

EXAMPLE 1A

The Example 1 Part C compound may also be prepared as described below.




A.



A mixture of (250.27 g, 1.0 mole, Robl, Jeffrey A.; Chen, Bang-Chi; Sun, Chong-Qing. U.S. Patent No. 6,620,821) and S-methylisothiuronium sulfate (162.84 g, 0.585 mole) in 750 mL HMPA was heated with stirring at 100°C for 24h, allowed to come to RT and diluted with EtOAc. The

mixture was washed sequentially with sat. NaHCO_3 and brine, dried over sodium sulfate and concentrated to afford 286 g of the title compound.

B.




5

To a solution of the title compound from step A (286 g, 0.887 mole) in 1.5 L MeOH was added DDQ (154 g) in small portions with stirring at -40°C to -20°C . The mixture was allowed to come to RT and stirred for 30 min. This was diluted with water and the resulting solid was isolated and washed with 1:1 water-ethanol to give the title compound as a white solid (221 g).

10


C.



15

This compound was prepared from the step B compound in a manner similar to that described for the title compound of step B, Example 1.


D.



20

Hydrogen peroxide (30%, 500 mL) was added at RT to a stirred solution of the compound from step C (424 g, 1.45 mole), ammonium heptamolybdate tetrahydrate (26.8 g, 0.022 mole) and tricaprylmethylammonium chloride Aliquat® 336, Aldrich) (58.7 g, 0.145 mole) in CH₂Cl₂ (3 L) over 1h (exotherm observed causing the solvent to reflux). The reaction mixture was stirred at RT for 3h, washed sequentially with water, sat. sodium thiosulfate and water. The organic layer was dried and concentrated to afford 470 g of the title compound.


E.




10

This compound was prepared from the step D compound in a manner similar to that described for the step C compound of Example 1.

15


EXAMPLE 2

A.




A mixture of 2H-Pyrazol-3-ylamine (3 g) and methyl iodide (5.13 g) in 150
5 mL THF was stirred for 1h at RT followed by the addition of potassium carbonate (4.5
g). The mixture was stirred at RT for an additional 1.5h, diluted with methylene
chloride, filtered and the filtrate was concentrated to afford a crude mixture of
products. This was subjected to flash chromatography (silica gel/methylene chloride-
methanol-NH₄OH 90:10:1) to afford a 1:1 mixture of 2-Methyl-2H-pyrazol-3-ylamine
10 and Methyl-(2H-pyrazol-3-yl)-amine (0.8 g). A solution of this mixture in 5mL N-
methylpyrrolidone (NMP) was added was added to a stirred mixture of the title
compound of example 1, step A (3 g, 8.0 mmol) and potassium carbonate (1.5 g) in 15
mL NMP. The mixture was stirred at RT for 14h, diluted with methylene chloride,
washed with water and the organic phase was dried (MgSO₄) and concentrated to give
15 crude product. This was subjected to flash chromatography (silica gel/hexane-EtOAc
9:1 to 2:1 gradient) to afford 0.75 g of the title compound (as well 1.35 g of the
starting unreacted sulfone).

B.




Potassium hydride (washed, 24 mg, 0.59 mmol) was added to a stirred solution of the title compound from step A (94 mg, 0.245 mmol) and 4-methoxybenzyl chloride (42.2 mg, 0.27 mmol) in 0.5 mL DMF at RT. After stirring for 1h at RT the mixture was quenched with sat. NaHCO₃, extracted with methylene chloride, dried and concentrated. The crude product was purified by flash chromatography (silica gel/hexane-EtOAc 80:20) to give 40 mg of the title compound as a gummy solid.

C.




The compound from step B (0.3 g) was reduced using DIBAL as described for the synthesis of the title compound of Example 1, step B to give 0.15 g of the title compound.

D.



The compound from step C (100 mg) was oxidized as described for the
5 synthesis of the title compound of Example 3, step F to give 75 mg of the title compound.


E.



10


This compound was prepared as described for the title compound of Example
1, step D.

F.



A solution of the compound from step E (90 mg) in methylene chloride (5 mL)
 5 was treated with TFA (0.5 mL) at RT for 6h. The mixture was washed with sat.
 NaHCO₃, dried and concentrated to give the title compound as a gummy solid (75mg).


G.




10

To a solution of the compound from step F (10 mg) in THF (0.1 mL) was
 added 1N NaOH (0.022 mL) and water (0.028 mL). The reaction mixture was stirred
 at RT for 0.5h, concentrated and the residue was subjected to reversed phase
 chromatography (C18 silica/MeOH-water 0:100 to 100:0 gradient) to afford the title
 15 compound as a white solid (5 mg), analytical LC retention time = 2.9 minutes (YMC
 ODS S5 4.6 mm X 50 mm column/methanol-water-TFA 10:90:0.1 to 90:10:0.1
 gradient over 4 minutes, 4 mL/min. flow rate); (M+H)⁺ 590 (carboxylic acid).

EXAMPLE 3




A.



5

To a stirred solution of




10

(3 g; Huebsch, Walter et al. Ger. Offen. (1992), DE 4023308; Huebsch, Walter et al. Eur. Pat. Appl. (1992), EP 465970) in 50 mL THF at -78°C was added 1M LAH in THF (25 mL). The mixture was stirred at 0°C for 1h, quenched by adding sat. NaHCO₃ and extracted with EtOAc. The organic layer was dried over sodium sulfate, concentrated to afford 2.65 g of the title compound.


15

B.



A mixture of the title compound of step A (2.65 g), trifluoroacetic acid (2 mL),
10% Pd/C (3 g) in 50 mL EtOH was shaken for 8h under hydrogen (50 psi, Parr
5 shaker). The mixture was filtered and the filtrate was concentrated to afford 1.9 g of
the title compound.


C.



10


To a solution of the title compound from step B (1.9 g) in 50 mL
tetrafluoroboric acid at -10°C was added 3.0 g sodium nitrite in small portions. The
mixture was stirred at -10°C for 30 minutes, added slowly to a saturated sodium
bicarbonate solution. The mixture was extracted with EtOAc, the organic phase was
15 dried over sodium sulfate, concentrated and the residue was purified by flash
chromatography (silica gel/methylene chloride) to give the title compound (1.55 g) as
a white solid.

D.




- To a stirred solution of the title compound from step C (15 g) 2-Ethyl-2H-pyrazol-3-ylamine (19.1 g) in THF (250 mL) at -78°C was added 1M lithium bistrimethylsilylamide (213 mL). The mixture was allowed to come to RT, then refluxed for 4h followed by the addition of saturated sodium bicarbonate solution. The mixture was extracted with EtOAc, the EtOAc layer was dried over sodium sulfate, concentrated and the residue was flash chromatographed (silica gel/hexane-
10 EtOAc 90:10 to 80:20) affording the title compound as a brown solid (12.8 g).

E.



- To a stirred solution of the title compound from step D (12.8 g) in dichloromethane (200 mL) at -78°C was added 1M DIBAL in dichloromethane (96.9 mL). The mixture was stirred at -78°C for 1h, quenched by adding water and saturated sodium potassium tartarate solution and stirred at RT for 2h. The mixture was extracted with dichloromethane, the organic layer was dried over sodium sulfate
20 and concentrated to afford the title compound (11 g) as a white solid.


F.



To a stirred solution of the title compound of step E (11 g) in DMF (50 mL)
5 and dichloromethane (300 mL) was added Dess-Martin's periodinane (12.6 g). The
mixture was stirred at RT for 1h, washed with saturated sodium bicarbonate solution,
dried over sodium sulfate and concentrated. The crude product was flash
chromatographed (silica gel/hexane-EtOAc 80:20) to afford the title compound (7.0 g)
as a brown solid.


10

G.




To a stirred solution of the title compound from step F (7.0 g) in methylene
15 chloride (100 mL) was sequentially added di-tert-butyl dicarbonate (12.5 g) and 4-
dimethylaminopyridine (DMAP, 7.01 g). The mixture was stirred at RT for 5h,
concentrated and the residue was subjected to flash chromatography (silica
gel/hexane-EtOAc 85:15) to give the title compound (7.0 g) as a brown solid.

H.




This compound was prepared from the title compound of step G as described
 5 for the synthesis of the title compound of Example 1, step D.


L.



10 To a stirred solution of the title compound of step H (11.0 g) in 90 mL
 methylene chloride at -15°C was added trifluoroacetic acid (90 mL). The mixture was
 stirred at -15°C for 3h, poured into a cold solution of 3N NaOH (467 mL),
 concentrated and the residue subjected to reversed phase chromatography (C18
 silica/methanol-water 0:100 to 100:0 gradient) to afford the title compound as a white
 15 solid (4.0 g); analytical LC retention time = 1.83 minutes (YMC ODS S5 4.6 mm X
 50 mm column/methanol-water-phosphoric acid 10:90:0.2 to 90:10:0.2 gradient over 4
 minutes); (M+H)⁺ 497 (carboxylic acid).


EXAMPLE 4

5 A.




To a stirred solution of the title compound of Example 2 step D (200 mg) in THF (5 ml) at -78 °C was added 1.0M lithium bistrimethylsilylamide (505 µl, the
10 reaction mixture was stirred at -78 °C for 15 minutes. Iodomethane (200 µl) was added to the reaction mixture, the mixture was allowed to come to RT and was stirred for an additional 1 hour. The mixture was diluted with saturated sodium bicarbonate solution (30 ml) and was extracted with ethyl acetate (30 ml). The ethyl acetate layer
15 was dried over sodium sulfate and concentrated. The crude product was purified by flash chromatography (silica gel/hexane-EtOAc 90:10 to 70:30 gradient) to give the title compound as a clear gum (164 mg).

B.




The title compound was prepared from the title compound of step A as
5 described for the synthesis of the title compound of Example 3 step E.

C.



10 The title compound was prepared from the title compound of step B as
described for the synthesis of the title compound of Example 3 step F.


D.



15

The title compound was prepared from the title compound of step C as described for the synthesis of the title compound of Example 3 step H.


E.



5


The title compound was prepared from the title compound of step D as described for the synthesis of the title compound of Example 3 step I; analytical LC retention time = 26.7 minutes (YMC ODS S5 6 mm X 150 mm column/methanol-water-phosphoric acid 10:90:0.2 to 90:10:0.2 gradient over 30 minutes, 1.5 mL/min. flow rate); $(M+H)^+$ 511 (carboxylic acid).

EXAMPLE 5




15

A.




- To a stirred solution of the title compound of Example 3 step D (200 mg) in THF (5 ml) at -78 °C was added 1.0M lithium bistrimethylsilylamide (505 μ l), the reaction mixture was stirred at -78 °C for 15 minutes. Methane sulfonyl chloride (78 μ l) was added to the reaction mixture at -78 °C, the mixture was stirred at -78 °C for 1 hour. The mixture was diluted with saturated sodium bicarbonate solution (30 ml) and was extracted with ethyl acetate (30 ml). The ethyl acetate layer was dried over sodium sulfate and concentrated. The crude product was purified by flash chromatography (silica gel/hexane-EtOAc 90:10 to 70:30 gradient) to give the title compound as a brown gum (200 mg).

B.




The title compound was prepared from the title compound of step A as described for the synthesis of the title compound of Example 3 step E.

C.




The title compound was prepared from the title compound of step B as
5 described for the synthesis of the title compound of Example 3 step F.

D.



10 The title compound was prepared from the title compound of step C as
described for the synthesis of the title compound of Example 3 step H.






E.


















15








The title compound was prepared from the title compound of step D as described for the synthesis of the title compound of Example 3 step I. Analytical LC retention time = 23.5 minutes (YMC ODS S5 6 mm X 150 mm column/methanol-water-phosphoric acid 10:90:0.2 to 90:10:0.2 gradient over 30 minutes, 1.5 mL/min. flow rate); (M+H)⁺ 575 (carboxylic acid).







The following compounds were prepared employing the procedure set out in Examples 1 and 2:








Example No.	Structure	MS [M+H] ⁺
6		535
7		471
8		485
9		457
10		470








Example No.	Structure	MS [M+H] ⁺
11		484
12		498
13		542
14		484
15		526
16		526
17		532

Example No.	Structure	MS [M+H] ⁺
18		514
19		473
20		487
21		471
22		550
23		552
24		514
25		531







Example No.	Structure	MS [M+H] ⁺
26		470
27		452
28		452
29		472
30		486
31		454
32		467




Example No.	Structure	MS [M+H] ⁺
33		468
34		550
35		481
36		467
37		467
38		546

Example No.	Structure	MS [M+H] ⁺
39		501
40		542
41		497
42		575
43		527
44		567
45		545




Example No.	Structure	MS [M+H] ⁺
46		468
47		509
48		484
49		527
50		605
51		575
52		508




Example No.	Structure	MS [M+H] ⁺
53		611
54		630
55		535
56		485
57		549
58		548
59		548

Example No.	Structure	MS [M+H] ⁺
60		484
61		598
62		578
63		581
64		520
65		534

Example No.	Structure	MS [M+H] ⁺
66		467
67		541
68		471


The following compounds were prepared employing the procedure set out in Examples 3, 4 and 5:

Example No.	Structure	MS [M+H] ⁺
69		497
70		485
71		483

Example No.	Structure	MS [M+H] ⁺
72		561
73		563
74		499

WHAT IS CLAIMED IS:

1. A compound of the formula



5

wherein X is N or CR₅;

R₁ and R₂ are the same or different and are independently selected from H, alkyl, alkoxyalkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl or

10 cycloheteroalkyl;

R₃ is aryl, heteroaryl, cycloalkyl or cycloheteroalkyl;


R₄ is H, alkyl, cycloalkyl, haloalkyl, alkoxyalkyl, alkylthioalkyl, alkylsulfonyl, arylsulfonyl, alkoxycarbonyl, aryloxy carbonyl, heteroaryloxy carbonyl,

alkylaminocarbonyl, arylaminocarbonyl, alkylthiocarbonyl, heteroarylaminocarbonyl,

15 alkylaminosulfonyl, alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl or

heteroarylsulfonyl;


R₅ is H or lower alkyl;



20

R₆ is H, or lower alkyl or a metal;

R₇ is H or lower alkyl;

and  represents a single bond or a double bond (which may be cis or trans);

or a pharmaceutically acceptable salt thereof where R_6 is H, or ester thereof, a prodrug ester thereof, and all stereoisomers thereof.

5

2. The compound as defined in Claim 1 where X is N.

3. The compound as defined in Claim 1 where X is CR_5 .

10

4. The compound as defined in Claim 1 wherein the Z group is in form of a free acid, a physiologically acceptable and hydrolyzable ester or δ lactone thereof, or an alkali metal salt, alkaline earth metal salt, an amine salt or an amino acid salt.

15

5. The compound as defined in Claim 1 wherein

R_1 and R_2 are independently selected from alkyl, cycloalkyl and aryl;

R_3 is aryl, heteroaryl or cycloheteroalkyl; and

R_4 is H, alkyl, lower alkylcarbonyl, lower alkylsulfonyl or lower alkoxycarbonyl.

20


6. The compounds as defined in Claim 1 wherein R_1 is aryl; and

R_2 is alkyl or cycloalkyl;

R_3 is aryl, heteroaryl, cycloheteroalkyl;

R_4 is H, lower alkyl, lower alkylcarbonyl, lower alkylsulfonyl or lower alkoxycarbonyl;

25

and  is a double bond.

7. The compound as defined in Claim 1 wherein

R_1 is 4-fluorophenyl, 4-fluoro-3-methylphenyl or 3,5-dimethylphenyl;


R_2 is isopropyl, t-butyl or cyclopropyl;


30

R_3 is aryl which is phenyl, cycloheteroalkyl which is tetrahydrothiophene dioxide, a heteroaryl which is a pyrazole, a thiadiazole, a pyrazine, pyrimidine, a

benzimidazole, a triazole, a tetrazole, a pyridyl, a thiazole, an oxazole or an isoxazole, each of which may be optionally substituted with 1, 2 or 3 substituents which may be the same or different and which can be cycloheteroalkyl, heteroaryl, alkyl, halogen, carboxyl, alkoxycarbonyl, alkylaminocarbonyl, or alkoxy;

5 R_4 is H, methyl, methylcarbonyl, methoxycarbonyl or methanesulfonyl;


 is a trans double bond; and



10 or an alkali or alkaline earth metal salt thereof or an amino acid salt thereof or an amine salt thereof.

8. The compound as defined in Claim 7 wherein X is N or CR₅.

15 9. The compound as defined in Claim 1 having the formula I




or an alkali or alkaline earth metal salt thereof, or an amino acid salt, or an amine salt thereof, wherein R₈ and R₉ are the same or different and independently selected from H, halogen or alkyl; and

R₂ is alkyl or cycloalkyl;

R₃ is aryl, heteroaryl or cycloheteroalkyl;

R₄ is H, C₁-C₄ alkyl, C₁-C₄ alkylcarbonyl, C₁-C₄ alkoxycarbonyl or C₁-C₄



25 alkylsulfonyl.






R_4 is H, methyl, methylcarbonyl, methoxycarbonyl or methanesulfonyl.

5

11. A compound having the structure



10




5

where R_6 is H, an alkyl or an alkali metal salt.

12. The compound as defined in Claim 11 wherein R_6 is methylamine,
 10 ammonium, dicyclohexylamine, t-butyl, Na or Ca.


13. A compound having the structure

A.




5

where R_1 and R_2 are the same or different and are independently selected from alkyl, alkoxyalkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl or cycloheteroalkyl; and



10

B.




where R_1 and R_2 are as defined above, and

15


R_3 is aryl, heteroaryl, cycloalkyl or heterocycloalkyl;

R_4 is H, alkyl, cycloalkyl, haloalkyl, alkoxyalkyl, alkylthioalkyl, alkylsulfonyl, arylsulfonyl, alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, alkylaminosulfonyl, acyl, arylcarbonyl, heteroarylcarbonyl or heteroarylsulfonyl; and



20

C.




5 where R₁ and R₂ are as defined above;

R₅ is H, lower alkyl or -COOH, COOalkyl, -CH₂OH or alkylO;


Q₂ is H₂N-, F, R₃HN- or R₃R₄N-,

D.



10

where R₁, R₂ and R₅ are as defined above and Q₃ is R₃HN-, R₃R₄N- or
(where PG is a protecting group),



15

14. A pharmaceutical composition comprising a compound as defined in Claim 1 and a pharmaceutically acceptable carrier therefor.

15. A pharmaceutical combination comprising the HMG CoA reductase inhibitor compound as defined in Claim 1 and one or more hypolipidemic agents or lipid-lowering agents, or lipid agents, or lipid modulating agents, and/or one or more other types of therapeutic agents including antidiabetic agents, anti-obesity agents, antihypertensive agents, platelet aggregation inhibitors, anti-dementia agents, anti-Alzheimer's agents, anti-osteoporosis agents, and/or hormone replacement therapeutic

agents, and/or other cardiovascular agents, anti-anginal agents, anti-arrhythmic agents, anti-atherosclerosis agents, anti-inflammatory agents, anti-arthritis agents, anti-platelet agents, anti-heart failure agents, anti-cancer agents, anti-infective agents, hormone replacement agents, growth hormone secretagogues, selective androgen receptor
5 modulators, and/or immunomodulatory agents.

16. The combination as defined in Claim 15 wherein the hypolipidemic agent or lipid-lowering agent or other lipid agent or lipid modulating agent or anti-atherosclerotic agent, which is employed comprises 1,2,3 or more MTP inhibitors,
10 squalene synthetase inhibitors, fibric acid derivatives, PPAR α agonists, PPAR dual α/γ agonists, PPAR δ agonists, ACAT inhibitors, lipoxygenase inhibitors, cholesterol absorption inhibitors, ileal Na⁺/bile acid cotransporter inhibitors, upregulators of LDL receptor activity, cholesteryl ester transfer protein inhibitors, bile acid sequestrants, or nicotinic acid and derivatives thereof, ATP citrate lyase inhibitors, phytoestrogen
15 compounds, an HDL upregulators, LDL catabolism promoters, antioxidants, PLA-2 inhibitors, antihomocysteine agents, HMG-CoA synthase inhibitors, lanosterol demethylase inhibitors, or sterol regulating element binding protein-I agents.

17. The pharmaceutical combination as defined in Claim 15 comprising said
20 HMG CoA reductase inhibiting compound and an antidiabetic agent which comprises 1,2,3 or more antidiabetic agents or antihyperglycemic agents which is an insulin secretagogue or insulin sensitizer, which is selected from biguanides, sulfonyl ureas, PTP-1B inhibitors, aldose reductase inhibitors, glucosidase inhibitors, PPAR γ agonists, PPAR α agonists, PPAR δ antagonists or agonists, α P2 inhibitors, PPAR α/γ
25 dual agonists, dipeptidyl peptidase IV (DP4) inhibitors, SGLT2 inhibitors, glycogen phosphorylase inhibitors, and/or meglitinides, insulin, slow release insulin-BasulinTM, and/or glucagon-like peptide-1 (GLP-1) or a mimetics thereof.

18. The combination as defined in Claim 17 wherein the antidiabetic agent is
30 1, 2, 3 or more of metformin, glyburide, glimepiride, glipyrider, glipizide, chlorpropamide, gliclazide, acarbose, miglitol, pioglitazone, troglitazone,

rosiglitazone, insulin, GI-262570, isaglitazone, JTT-501, NN-2344, L895645, YM-440, R-119702, AJ9677, repaglinide, nateglinide, KAD1129, AR-HO39242, GW-409544, KRP297, AC2993, LY315902, P32/98, NVP-DPP-728A, NVP-LAF-237, muraglitazar, BMS 477,188, and/or BMS 538,305.

5

19. The combination as defined in Claim 15 wherein the other type of therapeutic agent which may be optionally employed is 1, 2, 3 or more of an anti-obesity agent which is a beta 3 adrenergic agonist, a lipase inhibitor, a serotonin (and dopamine) reuptake inhibitor, an α 2 inhibitor, a thyroid receptor beta drug, an
10 anorectic agent, a PTP-1B inhibitor, a CCKA agonist, a neuropeptide Y antagonist, a melanocortin-4-receptor agonist, a PPAR modulator which is a PPAR γ antagonist, PPAR α agonist, and/or PPAR δ antagonist, a leptin inhibitor such as a leptin receptor activator, a fatty acid oxidation upregulator or inducer, a 5HT2c-agonist or an ACC inhibitor.

15

20. The combination as defined in Claim 15 wherein the anti-obesity agent is orlistat, ATL-962, AJ9677, L750355, CP331648, sibutramine, topiramate, axokine, dexamphetamine, phentermine, phenylpropanolamine, and/or mazindol, P57 or CP-644673 (Pfizer); the lipid modulating agent is an MTP inhibitor, a squalene synthetase
20 inhibitor, a fibric acid derivative, an upregulator of LDL receptor activity, a lipoxxygenase inhibitor, or an ACAT inhibitor and the other lipid agent is a cholesteryl ester transfer protein inhibitor; and the antihypertensive agent employed is an ACE inhibitor, angiotensin II receptor antagonist, NEP inhibitor, a NEP/ACE inhibitor, a calcium channel blocker, a T-channel calcium antagonist, a β -adrenergic blocker, a
25 diuretic, a α -adrenergic blocker, a dual action receptor antagonist (DARA), or a heart failure drug, wherein the antihypertensive agent is an ACE inhibitor which is captopril, fosinopril, enalapril, lisinopril, quinapril, benazepril, fentiapril, ramipril or moexipril;

an NEP/ACE inhibitor which is omapatrilat, gemopatrilat, or CGS 30440;
30 an angiotensin II receptor antagonist which is irbesartan, losartan or valsartan; amlodipine besylate, prazosin HCl, verapamil, nifedipine, nadolol, propranolol, or

clonidine HCl, carvediol, atenolol, hydrochlorothiazide, torasemide, furosemide, spironolactone or indapamide; and

the lipid modulating agent is fenofibrate, gemfibrozil, clofibrate, avasimibe, TS-962, MD-700, cholestagel, torcetrapib, JTT-705, niacin, LY295427, muraglitazar, and/or ezetimibe.

21. The combination as defined in Claim 15 wherein the HMG CoA reductase inhibitor is in combination with a platelet aggregation inhibitor.

22. The combination as defined in Claim 21 wherein the platelet aggregation inhibitor is aspirin, clopidogrel, ticlopidine, dipyridamole, ifetroban, abciximab, tirofiban, eptifibatide, anagrelide, CS-737, melagatran, ximelagatran, razaxaban, or a combination of clopidogrel and aspirin.

23. The combination as defined in Claim 15 wherein the other therapeutic agent is an anti-Alzheimer's agent or anti-dementia agent, which is tacrine HCl (Cognex®), donepezil (Aricept®), a γ -secretase inhibitor, a β -secretase inhibitor and/or antihypertensive agent;

an antiosteoporosis agent, which is parathyroid hormone, a bisphosphonate, alendronate, a Ca receptor agonist or a progestin receptor agonist;

a hormone replacement therapeutic agent, which is a selective estrogen receptor modulator (SERM);

a tyrosine kinase inhibitor;

a selective androgen receptor modulator;

an antiarrhythmic agent, which is a β -blocker, or a calcium channel blocker, or an α -adrenergic blocker;

coenzyme Q sub. 10;

an agent that upregulates type III endothelial cell nitric acid syntase;

a chondroprotective compound which is polysulfated glycosaminoglycan (PSGAG), glucosamine, chondroitin sulfate (CS), hyaluronic acid (HA), pentosan polysulfate (PPS), doxycycline or minocycline;

a cyclooxygenase (COX)-2 inhibitor, which is Celebrex® (Searle) or Vioxx® (Merck) or a glycoprotein IIa/IIIb receptor antagonist;
a 5-HT reuptake inhibitor;
a growth hormone secretagogue;
5 an anti-atherosclerosis agent;
an anti-infective agent, or an immunosuppressant for use in transplantation, or
an antineoplastic agent.

24. A method for treating hypercholesterolemia, dyslipidemia,
10 hyperlipidemia, hyperlipoproteinemia, LDL Pattern B, LDL Pattern A,
hypertriglyceridemia or atherosclerosis, or Alzheimer's disease or osteoporosis,
inhibiting cholesterol biosynthesis or lowering blood serum cholesterol levels and/or
modulating blood serum cholesterol levels, lowering LDL cholesterol and/or
increasing HDL cholesterol, and/or lowering triglycerides, or treating dyslipidemia,
15 mixed dyslipidemia, LDL Pattern B, LDL Pattern A, hyperlipidemia,
hypercholesterolemia, hypo α -lipoproteinemia, hyperlipoproteinemia or
hypertriglyceridemia, and other aberrations of apolipoprotein B metabolism, or
reducing levels of Lp(a), or treating or preventing other cholesterol-related diseases, or
treating or preventing or reversing progression of atherosclerosis, or preventing or
20 treating Alzheimer's disease, or preventing or treating osteoporosis and/or osteopenia,
or reducing inflammatory markers, reducing C-reactive protein, or preventing or
treating low grade vascular inflammation, or preventing or treating stroke, or
preventing or treating dementia, or preventing and treating coronary heart disease, and
primary and secondary prevention of myocardial infarction, or preventing or treating
25 stable and unstable angina, or primary prevention of coronary events, or secondary
prevention of cardiovascular events, or preventing or treating peripheral vascular
disease, preventing or treating peripheral arterial disease, or preventing or treating
acute vascular syndromes, or preventing or reducing the risk of undergoing
myocardial revascularization procedures, or preventing or treating microvascular
30 diseases such as nephropathy, neuropathy, retinopathy and nephrotic syndrome, or
preventing or treating hypertension, preventing or treating diabetes, especially Type 2
diabetes, and related diseases, insulin resistance, hyperglycemia, hyperinsulinemia,

elevated blood levels of fatty acids or glycerol, obesity, LDL Pattern B, LDL Pattern A, Syndrome X, diabetic complications, dysmetabolic syndrome, and related diseases, and sexual dysfunction, preventing and treating malignant lesions, premalignant lesions, gastrointestinal malignancies, liposarcomas and epithelial tumors, cancer-induced asthenia (fatigue), irritable bowel syndrome, Crohn's disease, gastric ulceritis, and gallstones, and HIV infection, drug-induced lipodystrophy, and proliferative diseases, for improving coagulation homeostasis, reducing PAI-1 activity, reducing fibrinogen, and/or reducing platelet aggregation, and/or improving endothelial function, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a compound as defined in Claim 1.

25. A method for treating cholesterol related diseases, diabetes and related diseases, cardiovascular diseases, cerebrovascular diseases, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a combination of a compound as defined in Claim 15 and a hypolipidemic agent, and/or lipid modulating agent and/or antidiabetic agent and/or cardiovascular agent, cerebrovascular agent, and/or other type of therapeutic agent, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of such combinations.

20

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2004/031212

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D403/12 C07D401/12 C07D413/12 C07D417/12 C07D239/42
A61K31/506 A61P3/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data, PAJ, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 416 383 A (BAYER AG) 13 March 1991 (1991-03-13) examples	1-25
Y	EP 0 521 471 A (SHIONOGI SEIYAKU KABUSHIKI KAISHA) 7 January 1993 (1993-01-07) examples	1-25



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

7 February 2005

Date of mailing of the international search report

15/02/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Menegaki, F

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2004/031212

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: —
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 24, 25 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US2004/031212

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0416383 A	13-03-1991	DE 3929507 A1	07-03-1991
		AU 637632 B2	03-06-1993
		AU 6217090 A	14-03-1991
		CA 2024576 A1	07-03-1991
		DD 299295 A5	09-04-1992
		EP 0416383 A2	13-03-1991
		HU 56546 A2	30-09-1991
		IE 903231 A1	13-03-1991
		IL 95563 A	24-06-1994
		JP 3093773 A	18-04-1991
		NZ 235144 A	25-06-1992
		PT 95194 A	22-05-1991
		US 5145857 A	08-09-1992
		ZA 9007054 A	31-07-1991
EP 0521471 A	07-01-1993	AT 197149 T	15-11-2000
		CA 2072945 A1	02-01-1993
		CY 2226 A	18-04-2003
		DE 69231530 D1	30-11-2000
		DE 69231530 T2	13-06-2001
		DK 521471 T3	05-02-2001
		EP 0521471 A1	07-01-1993
		ES 2153824 T3	16-03-2001
		GR 3035189 T3	30-04-2001
		HK 1011986 A1	13-07-2001
		HU 220624 B1	28-03-2002
		HU 61531 A2	28-01-1993
		JP 2648897 B2	03-09-1997
		JP 5178841 A	20-07-1993
		KR 9605951 B1	06-05-1996
		LU 91042 A9	24-11-2003
		NL 300125 I1	01-07-2003
		PT 521471 T	30-04-2001
		US RE37314 E1	07-08-2001
		US 5260440 A	09-11-1993